Final Conference Program - aatod

NATIONAL CONFERENCE 

Building 

Partnerships: 

Advancing 

Treatment & 

Recovery 

Conference Program 

CHICAGO 2O1O 

OCTOBER 23–27, 2010 

Hilton Chicago • Chicago, Illinois 

www.aatod.org

Building 

Partnerships: 

Advancing 

Treatment & 

Recovery 

Conference 

Objectives: 

• To identify and provide 

new information of critical 

importance to the field 

• To examine and evaluate 

implications of new information 

for clinicians, administrators 

and policy makers 

• To demonstrate techniques 

for improving clinical and 

program administration 

• To promote the benefits 

of community partnership 

Conference Planning 

Committee 

Susan McKnight, MPH 

Conference Chair 

Mark W. Parrino, MPA 

President 

American Association for the Treatment of 

Opioid Dependence, Inc. 

Carleen Maxwell, MPH 

Project Director 



Angelina Budija 

Administrative Coordinator 



Alexandra Springer, CMP 

Meetings and Exhibits Manager 

Talley Management Group, Inc. 

BOARD OF DIRECTORS 


President 

George Stavros, MD 

Second Vice-President 

Michael Rizzi 

Treasurer 

Jina K. Thalmann, LCSW 

Secretary 

BOARD MEMBERS 

Richard Bilangi, MS 

Roye T. Brown, MS 

Peter Coleman, MS 

Brian Crissman, BA 

Eric Ennis, LCSW 

Emilia Figueroa-Guillen, MD 

Steve Flora 

Richard Froncillo, LCDS 

James B. Graham 

Gregory Hardin, CADAC II 

Edward J. Higgins, MA 

Kenny House, LCAS 

Ron Jackson, MSW 

Edward G. Johnson, LPC 

Janice F. Kauffman, RN 

Jason Kletter, PhD 

Shirley Linzy, RN 

Kate Mahoney, LCSW 

Ira J. Marion, MA 

Brian McCarroll, DO 

Paul McLaughlin, MA 

Joel Millard, DSW 

Edward Ohlinger 

Stacey Pearce 

Keith E. Spare, MS 

Board Delegate TBD 

Board Delegate TBD 

NY 

AZ 

RI 

FL 

CT 

LA 

NY 

DC 

CO 

Mexico 

AL 

PA 

MD 

IN 

NJ 

NC 

WA 

SC 

MA 

CA 

NV 

IL 

NY 

MI 

CT 

UT 

VA 

GA 

MO 

ME 

OH 

2010 Conference 

Committees 

ACCREDITATION COMMITTEE 

Brian Crissman, Committee Chair 

AWARDS COMMITTEE 

Stacey Pearce, Committee Chair 

James B. Graham 

Jason Kletter, PhD 

Carrie Perkins 

Michael Rizzi 

HOSPITALITY COMMITTEE 

Tamika Whitehead, LCSW, Committee Chair 

M.J. Hodgins, CADC 

Margo Owen, LCPC 

Eve Packer, MS 

Armando Reyes, MHS 

INTERNATIONAL COMMITTEE 

Michael Rizzi, Committee Chair 

Icro Maremmani, MD 


PLENARY COMMITTEE 

Richard Weisskopf, Committee Chair 

Melody Heaps 



PUBLIC RELATIONS COMMITTEE 

Kate Mahoney, LCSW, Committee Chair 

VOLUNTEER COMMITTEE 

Brian Nottage, Committee Chair 

Sarah McHugh, LCPC 

Father Elwood Nyther, LCSW 

Maureen O’Grady 

Desiree Samangooie 

WORKSHOP COMMITTEE 

Ron Jackson, MSW, Committee Chair 

Terence A. Bardell, MA 

Amina Chaudhry, MD 

Walter Ginter, CMA 

Petra Jacobs, MD 

Karol Kaltenbach, PhD 

Megan Marx, MPA 

Lenette Pietscher, RN 

Michael Rizzi 

Craig V. Showalter, MD 

Susan Storti, PhD 

Joan Zweben, PhD

LETTER FROM THE CONFERENCE CHAIR 

Dear Colleagues, Patients, Advocates, Stakeholders and Friends: 

On behalf of the American Association for the Treatment of Opioid Dependence, Inc. (AATOD), and our hosts, the 

Illinois Department of Alcoholism and Substance Abuse (DASA) and IAMAAT – Illinois Association for Medication 

Assisted Addiction Treatment, it is my pleasure to welcome you to our 2010 AATOD Conference at the Hilton 

Chicago in the beautiful city of Chicago. 

Our conference planning committee has worked hard to make this conference a truly exceptional event. As you 

review the Plenary Sessions, Workshop Sessions and Hot Topic Roundtables as well as the Pre-Conference training 

opportunities, you will appreciate the efforts of our planners to provide you with an outstanding training and policy 

event focusing on opioid dependence and medication assisted treatment. 

I encourage you to participate in all our sessions, spend time in our exhibition hall, talking to the many vendors and 

exhibitors that support our field and view the displays including the poster presentations. Please take the opportunity 

to be heard at the hot topic roundtables. Attend the workshops, posters and other conference activities, packed 

with information and ideas to improve our programs and the treatment field. Take advantage of the clinic tours on 

Wednesday and make the most of your opportunity to speak with your peers and associates from various fields. 

The Awards Banquet on Tuesday evening is our elegant celebration at which time we honor those who have made 

significant contributions to our field. We hope everyone will join us for this poignant event. 

As this year’s conference focus is on Building Partnerships: Advancing Treatment and Recovery we want to 

especially welcome our affiliates that work with the same population but in different modalities. This includes law 

enforcement officials, social workers, family members of opiate dependent individuals, EMTs, children services, 

recovery home personnel and clinicians from chemical dependency programs that may not include Medication 

Assisted Treatment. 

Please take the time to enjoy the friendly and culturally diverse city of Chicago, which is especially beautiful in the 

autumn. Grant Park, the Magnificent Mile, Navy Pier, Lake Michigan, The Art Institute, Greek Town, Little Italy, 

Chinatown and many shops, restaurants and bars are all within walking distance or a short taxi ride. 

Finally, I ask that you help with the planning of the next conference by completing the evaluations at the end of each 

session and the whole conference, since these are carefully reviewed for your comments and needs. 

Enjoy the conference, the camaraderie and the beautiful city of Chicago. I look forward to meeting many of you. 


2010 Conference Chair 

NATIONAL CONFERENCE • CHICAGO 2O1O • OCTOBER 23–27, 2010 • WWW.AATOD.ORG

Schedule at a Glance (EVENTS AND TIMES LISTED ARE SUBJECT TO CHANGE) 

WEDNESDAY, 10/27 

TUESDAY, 10/26 

MONDAY, 10/25 

SUNDAY, 10/24 SATURDAY, 10/23 

7:00 a.m.–5:00 p.m. Registration Open 

8:00 a.m.–5:00 p.m. The Certified Medication Assisted Treatment Advocate (CMA) Training Course 

8:30 a.m.–5:00 p.m. Performance Improvement in Opioid Treatment Programs (maximum 50 participants) 

8:30 a.m.–5:00 p.m. Assessment and Treatment Planning Workshop (maximum 50 participants) 

9:00 a.m.–4:00 p.m. Clinical Supervision and Professional Development of the Substance Abuse Counselor 

5:00 p.m.–8:30 p.m. AATOD Open Board Meeting 


8:00 a.m.–5:30 p.m. Opioid Maintenance Pharmacotherapy: A Course for Clinicians 

8:30 a.m.–5:00 p.m. Partnership Development for OTPs 

8:30 a.m.–12:30 p.m. Buprenorphine for Nurses 

9:00 a.m.–12:00 p.m. Opioid Treatment Program Accreditation–Town Hall Meeting 

9:00 a.m.–12:00 p.m. US and Vietnam: Celebrating 15 Years of Relations, 1995–2010 

9:00 a.m.–5:30 p.m. NIATx OTP Project (invitation only) 

9:30 a.m.–12:00 p.m. HIV Testing, Counseling & Treatment in OTPs–New Research Findings and Clinical Implications 

1:00 p.m.–5:00 p.m. Minimize Liability, Manage Risk, Ensure Patient Safety: Effective Strategies in Outpatient 

Methadone Treatment 

1:00 p.m.–5:00 p.m. European Opiate Addiction Treatment Association (EUROPAD) 

5:30 p.m.–7:30 p.m. Welcome Reception 

7:30 p.m.–8:30 p.m. Methadone Anonymous Meeting (Open) 


7:30 a.m.–8:30 a.m. Continental Breakfast in Exhibit Hall 

7:30 a.m.–9:30 a.m. Exhibits 

7:30 a.m.–4:30 p.m. Posters in Exhibit Hall (Exhibit Hall closed 9:30 a.m.–11:30 a.m.) 

8:45 a.m.–10:15 a.m. Opening Plenary Session—Building Partnerships: Advancing Treatment & Recovery 

10:30 a.m.–12:00 p.m. Workshop Sessions 

11:30 a.m.–4:30 p.m. Exhibits 

12:00 p.m.–1:30 p.m. Lunch (on your own) 

1:30 p.m.–3:00 p.m. Workshop Sessions / Hot Topic Roundtables 

3:00 p.m.–4:00 p.m. Exhibitors Networking Refreshment Break in Exhibit Hall 

4:00 p.m.–5:30 p.m. Workshop Sessions 

6:00 p.m.–8:00 p.m. Digital Access to Medication (D-ATM) Town Hall: Using Technology in Opioid Treatment to Prepare for 

Disasters & Promote Continuity of Care 



7:30 a.m.–8:30 a.m. Continental Breakfast in Exhibit Hall 

7:30 a.m.–8:45 a.m. Poster Author Session 

7:30 a.m.–1:30 p.m. Exhibits 

7:30 a.m.–1:30 p.m. Posters in Exhibit Hall 

8:45 a.m.–10:15 a.m. Middle Plenary Session—Addiction, Pharmacology and the Criminal Justice System 

10:30 a.m.–12:00 p.m. Workshop Sessions 

12:00 p.m.–1:30 p.m. Lunch (on your own) 

1:30 p.m.–3:00 p.m. Workshop Sessions 

7:00 p.m.–9:30 p.m. Awards Banquet 



7:00 a.m.–8:00 a.m. Continental Breakfast 

8:00 a.m.–9:30 a.m. Workshop Sessions 

9:45 a.m.–11:15 a.m. Workshop Sessions 

11:30 a.m.–12:45 p.m. Closing Plenary Session—The Partnership of the Field and the Federal Government: 

The Expansion of Healthcare Reform and Access to Quality Care 

1:00 p.m.–3:30 p.m. Clinic Tours (Sign-Up at Hospitality Table) 

2 AATOD National Conference | Building Partnerships: Advancing Treatment & Recovery

Pre-Conference Sessions 

Saturday, October 23, 2010 

8:00 a.m.–5:00 p.m. 

Continental A 

The Certified Medication Assisted Treatment 

Advocate (CMA) Training Course 

Walter Ginter, CMA, NAMA Recovery, New York, NY 

Nicholas Reuter, MPH, SAMHSA/CSAT, Rockville, MD 

Joycelyn Woods, MA, NAMA Recovery, New York, NY 

Laura McNicholas, MD, University of Pennsylvania, 

Philadelphia, PA 

Richard Weisskopf, SOTA, Division of Alcoholism and Substance 

Abuse, Illinois Department of Human Services, Chicago, IL 

Kerry Wolf, RN, NAMA Recovery, New York, NY 

The leading advocate and recovery organization for medication 

assisted treatment, the National Alliance for Medication Assisted 

Recovery (NAMA Recovery), has developed this training, believing 

that professionals, patients and families of patients can come 

together to work for a better understanding of methadone and 

medication assisted treatment. Previous trainings have shown that 

participants – both professionals and patients – are equally empowered. 

Therefore we encourage both patients and non-patients to 

become Certified Medication Assisted Treatment Advocates (CMA). 

This training is designed for non-clinicians and provides a basic 

understanding of the physiology of addiction and the use of medications 

to treat it (i.e. methadone and buprenorphine). Regulations at 

the federal, state and local levels are explained in simple terms for 

non-policy makers. 

With these goals in mind, the course presentation is constituted as 

follows: 

Medication Assisted Treatment – Basic clinical information about 

methadone and buprenorphine treatment. 

Addiction & Methadone – Current neuroscience about addiction in 

a language understandable to the non-clinician. 

Regulations & Accreditation – Current regulations explained by 

the federal agency that oversees methadone and buprenorphine 

treatment. 

State Opioid Treatment Authority (SOTA) – State regulations 

explained by the Illinois SOTA provide a view of working within state 

systems. 

Hands On Advocacy – Basic tools to work as an advocate and how to 

manage simple issues that advocates are confronted with including 

educating patients about their rights, handling grievances, legal 

issues and working within communities to benefit patients and treatment. 

Advocacy and The Media – Responding to negative media in newspapers, 

television, movies, etc. and writing response letters and 

letters to the editor. 

Systems Advocacy – Using advocacy to change policy and working 

within state and federal systems to improve the rights of patients. 

Certified Medication Assisted Treatment Advocate (CMA) – What 

is a Certified Medication Assisted Treatment Advocate, ethics of 

advocacy and the mechanism of certification and how it will professionalize 

those committed to advocacy. 

Participants will come away with the initial tools for basic advocacy 

to grow and develop into successful advocates. The course involves 

eight hours of rigorous training and fulfills the training requirement 

for Certification as a Medication Assisted Treatment Advocate 

(CMA). 

On site registration will be between 8 a.m. to 9 a.m. outside of the 

session room at the hotel. There is a separate registration fee of 

$50.00 for the pre-conference event. The fee includes all materials, 

2010/2011 membership in NAMA Recovery and the application for 

CMA. NAMA Recovery cannot guarantee a place to anyone not preregistered. 

Lunch is not provided. 

Sponsored by the National Alliance for Medication 

Assisted Recovery (NAMA Recovery) and 

Mallinckrodt (a Covidien Company). 

October 23–27, 2010 | Hilton Chicago, Chicago, Illinois 3



8:30 a.m.–5:00 p.m. 

Boulevard A 

Performance Improvement in Opioid Treatment 

Programs 

Brenda Gilliam–Jones, MPA, DB Consulting, Orlando, FL 

Bernhild Quintero, MA, DB Consulting, Altadena, CA 

The purpose of the Performance Improvement in Opioid Treatment 

Workshop is to provide attendees with a fast-paced workshop and an 

intense look at performance improvement in opioid treatment. The 

workshop provides participants with the knowledge, strategies and 

skills to implement or revise their organizations’ performance 

improvement programs. The training includes performance improvement 

theory; discussions of best practices in the implementation of 

performance improvement programs; and interactive exercises 

showing practical applications of performance improvement 

processes, such as data collection and analysis, use of performance 

improvement committees/functions to manage the process, and the 

integration of performance improvement into other organizational 

functions. 

MODULE DESCRIPTIONS 

Module One: Introduction to the Workshop 

The purpose of this module is to provide an overview of the workshop 

and create a positive environment that sets the tone for discussing 

and learning about performance improvement in opioid treatment 

facilities. 

Module Two: What is Performance Improvement 

The goal of this module is to create a common understanding of the 

terms and definitions used in the field of performance improvement 

that will be referenced during the workshop. 

Module Three: Developing an Organizational Culture for Performance 

Improvement 

The purpose of this module is to review the type of organizational 

culture required to plan and implement an effective, comprehensive 

performance improvement system. 

Module Four: Using Outcome Studies in PI Programs 

The goal of this module is to discuss the benefits and challenges of 

examining existing outcome studies in the opioid treatment field and 

explore how to develop clinic- or program-based OTP outcome 

studies. 

Module Five: The 12-Step Performance Improvement Process 

The purpose of this module is to facilitate, review and discuss the 

key elements of an effective performance improvement process. The 

module will also include strategies for addressing some of the challenges 

organizations encounter in performance improvement 

programs including data collection and analysis, writing outcome 

measures and evaluating plan effectiveness. 

Module Six: Planning to Move Forward 

The purpose of this module is to bring participants together to 

review lessons learned during the training, discuss how they will 

apply those lessons in their own organizations and develop specific 

action plans to address their organization’s performance improvement 

needs. 

Module Seven: Workshop Closing Activities 

The purpose of this module is to summarize the day of training, 

review participant expectations and give participants time to 

complete their workshop evaluation forms. 

For session effectiveness, participation is limited to first 50 

attendees who arrive for the session. 

Sponsored by the Substance Abuse and Mental 

Health Services Administration, Center for 

Substance Abuse Treatment (SAMHSA/CSAT). 

8:30 a.m.–5:00 p.m. 

Boulevard C 

Assessment and Treatment Planning Workshop 

for Opioid Treatment Programs 

Robert Johnson, MEd, Accreditation Readiness, LLC, 

Columbia, MO 

Cynthia Banfield-Weir, LICSW, Community Health Care, 

Chicopee, MA 

The goal of the Assessment and Treatment Planning Workshop is to 

emphasize the rationale for and the process of assessment and treatment 

planning. This workshop will explain how to provide a clear 

business case for assessment and treatment planning for internal 

and external audiences, and to develop a strategy to internalize 

assessment and treatment planning as an integral part of the treatment 

process. This session provides a blueprint for assessment and 

treatment planning that is primarily patient centered. 


MODULE DESCRIPTIONS 

Module One: Introduction to the Workshop 

The purpose of this module is to set the tone for the workshop and 

create an open environment for the participants to learn about 

assessment and treatment planning. 

Module Two: Introduction to Comprehensive Assessments 

The purpose of this module is to review the levels of assessments and 

to explore and review the components of a comprehensive assessment. 

Module Three: Writing an Interpretive/Integrated Summary 

This module gives participants an opportunity to practice using the 

data gathered in a comprehensive assessment to write an interpretive/ 

integrated summary. 

Module Four: Patient-Centered Treatment Planning 

The purpose of this segment of the workshop is to address the benefits 

and challenges of patient-centered treatment planning and to 

practice incorporating assessment data into patient-centered treatment 

plans. 

Module Five: Components and Development of Patient-Centered 

Treatment Plans 

The purpose of this module is to identify and review the components 

of a patient-centered treatment planning process and to provide an 

opportunity for the participants to use the data, knowledge and skills 

acquired during the workshop to create patient-centered treatment 

plans. 

Module Six: Putting It All Together 

The purpose of this module is to review the connection between a 

comprehensive assessment and patient-centered treatment planning. 






9:00 a.m.–4:00 p.m. 

Continental C 

Clinical Supervision and Professional Development 

of the Substance Abuse Counselor 

Live Supervision for the Clinical Supervisor 

Richard Gelb, New York, NY 

The goal of this workshop is to provide a practical understanding 

of—and professional competency in—the clinical supervision 

process using an in-depth study and analysis of clinical supervision 

case presentations. Based on the CSAT Treatment Improvement 

Protocol 52 (TIP), this seminar will use material from workshop 

participant’s supervisory sessions to demonstrate the application of 

clinical supervision theory and practice. Participants will be 

expected to present portions/segments of supervisory experiences, 

i.e., case presentations of supervisor: supervisee clinical supervision 

meetings, for in-depth study and analysis. 

Learning Objectives: 

1. Enhance skills in providing clinical supervision using a case study 

model; 

2. Learn different approaches for addressing and resolving supervisor: 

supervisee conflicts; 

3. Increase understanding of key clinical supervision issues: 

a. supervisory alliance; b. parallel process; c. boundary problems; 

d. cultural and contextual factors; ethical and legal issues. 

Note: Clinical Supervision is for experienced and practicing clinical 

supervisors in the behavioral health field. 




AATOD Open Board Meeting 

Waldorf Room 


5:00 p.m.–8:30 p.m. 

Sponsored by a grant from Addiction Treatment 

Providers Insurance Group 



Sunday, October 24, 2010 

8:00 a.m.–5:30 p.m. 

Waldorf 

Opioid Maintenance Pharmacotherapy: 

A Course for Clinicians 

Laura McNicholas, MD, Philadelphia Veterans Administration 

Medical Center, Philadelphia, PA 

Susan Neshin, MD, JSAS Healthcare, Inc., Asbury Park, NJ 

J. Thomas Payte, MD, Colonial Management Group, LP, 

Orlando, FL 

Trusandra Taylor, MD, JEVS Human Services, Philadelphia, PA 

This course is recommended for clinicians with experience and/or 

interest in the medication-assisted treatment of opioid dependence. 

This program provides basic and state-of-the-art information. The 

curriculum is updated to include current consensus guidance for 

best practice treatment for opioid addiction. Topics include over - 

view of opioid dependence, epidemiology, opioid pharmacology/ 

neurobiology; evidence-based treatment options, patient 

assessment/ selection, special populations, induction and maintenance 

protocols, pain management, drug-to-drug interactions, 

adverse effects, methadone deaths, managing medical/ psychiatric 

problems, drug testing, regulatory issues, an accreditation update, 

risk management and an overview of buprenorphine. 

Participants will receive a comprehensive syllabus with reference 

and resource materials. The curriculum will include relevant case 

study discussion with audience participation to facilitate the 

learning process. To further integrate the educational objectives, 

participants are encouraged to discuss challenging problems and 

clinical issues to facilitate understanding of didactic principles. 

Four experienced opioid treatment program medical directors will 

conduct the program, focusing on the goal for participants to acquire 

the essential knowledge and skills necessary to deliver safe and 

effective medication-assisted treatment for patients with opioid 

dependence. 

The $175.00 registration fee includes a morning coffee service, 

afternoon luncheon and the evening’s Welcome Reception. 

Sponsored by the American Association for the 

Treatment of Opioid Dependence, Inc. and the American 

Society of Addiction Medicine, in cooperation with the 

American Academy of Addiction Psychiatry and the 

American Osteopathic Academy of Addiction Medicine. 

Supported by the National Institute on Drug Abuse. 

AMA PRA Category 1 Credit approved. 

8:30 a.m.–5:00 p.m. 

Continental A 

Partnership Development for OTPs 

Maxine Fuller, MS, McKinley Group, Inc., Sandy Springs, GA 

Partnership development is a strategy that many organizations are 

using to enhance their ability to design, fund and provide services. 

The one-day Partnership Development for Opioid Treatment 

Programs Workshop will provide participants with the skills and 

tools necessary to identify, recruit and maintain effective partnerships. 

This is a hands-on and interactive workshop that will allow the 

participants to leave with a partnership development plan and effective 

implementation strategies and resources. 

In addition to the objectives stated above, completion of this workshop 

will enable participants to: 

• Determine if partnering is the correct strategy for their organizations 

• Identify partnership implementation tools and resources 

The topics the workshop will cover include: 

• Benefits and Challenges of Partnering 

• Partnership Assessment Exercise 

• Create Partnership Development Plans 






8:30 a.m.–12:30 p.m. 

Continental C 

Buprenorphine for Nurses 

Colleen LaBelle, RN, Boston Medical Center, Boston, MA 

Sara Azimi-Bolourian, MSN, SAMHSA, Rockville, MD 

Hilary Jacobs, LICSW, Bureau of Substance Abuse Services, 

Massachusetts Department of Public Health, Boston, MA 

This Pre-Conference session introduces a new guideline titled 

“Buprenorphine: A Guide for Nurses”. It was published by the 

Substance Abuse and Mental Health Services Administration 

(SAMHSA) as the 30th publication in the Technical Assistant Publication 

Series (TAP #30). This Pre-Conference session is intended to 

provide nurses with general information about buprenorphine products—Suboxone® 

(buprenorphine and naloxone) and Subutex® 

(buprenorphine)—for the pharmacological treatment of opioid 

addiction. It covers screening, assessment, and diagnosis of opioid 

dependence and its associated problems and contains detailed 

protocols for the use of buprenorphine under a variety of clinical 

scenarios, including the use of buprenorphine with patients who are 

experiencing co-occurring pain or psychiatric disorders, or chemical 

dependency involving more than one substance. 


The session also provides nurses with a comprehensive overview of 

nursing roles in screening and assessing the health status of patients 

who have addiction problems. Moreover, the session focuses on 

nurses’ instrumental roles in the development and ongoing monitoring 

of treatment plans for patients who are on buprenorphine 

treatment and counseling and referral for psychosocial treatment. 

This session will assist nurses in developing improved understanding 

of the complexities of addictions treatment, and will promote better 

treatment outcomes by utilizing a team approach to patients’ opioid 

dependence. 

Sara Azimi-Bolourian will provide introductory remarks and a brief 

overview of the federal requirements for buprenorphine prescription 

and nursing roles. 

Colleen LaBelle will lead the session afterwards and provide information 

on the pharmacology of buprenorphine, detailed protocols for the 

use of buprenorphine under a variety of clinical scenarios, and protocols 

on the use of buprenorphine for medically supervised withdrawal, 

for classifications of medically supervised withdrawal, and for maintenance 

treatment. She will also describe the advantages and challenges 

of providing office-based treatment. 




9:00 a.m.–12:00 p.m. 

Continental B 

Opioid Treatment Program Accreditation— 

Town Hall Meeting 

Megan Marx, MPA, The Joint Commission, Oakbrook Terrace, IL 

Mary Cesare-Murphy, PhD, The Joint Commission, Oakbrook 

Terrace, IL 

This session will provide Joint Commission accredited organizations 

with an update on changes/revisions planned for accreditation standards 

and elements of performance in the Comprehensive Accreditation 

Manual for Behavioral Health Care (CAMBHC). The Joint 

Commission has recently completed a standards improvement initiative 

aimed at streamlining standards and elements of performance, 

and tailoring the survey process. A review of these changes, as well 

as a review of changes made to the format and structure of the 

CAMBHC electronically, to more effectively utilize the manual in 

their quality improvement processes and their continuous accreditation 

readiness efforts, will be discussed. 

We also intend to have our OTP account representatives and standards 

interpretation staff available during this session to meet with 

the organizations face-to-face and provide feedback to them about 

the survey application process and standards interpretation. We 

intend to use a Q&A format for this part of the session, after pro - 

viding participants with background information about the roles and 

responsibilities these two work groups represent. 

The two speakers will share time equally during the presentation. 

The account representatives and the standards interpretation staff 

member will participate during the last 30–45 minutes of the presentation, 

as needed. 

Sponsored by The Joint Commission. 

9:00 a.m.–12:00 p.m. 

Marquette 

US and Vietnam: Celebrating 15 Years 

of Relations, 1995-2010 

The efforts of AATOD and EUROPAD to create a world federation 

dedicated to the treatment and understanding of opioid dependence 

has far reaching influence. We are fortunate to have a delegation 

from Vietnam making a presentation at this conference. Under the 

sponsorship of PEPFAR -VN, and coordinated by the Substance 

Abuse and Mental Health Services Administration (SAMHSA), representatives 

from Vietnam will discuss the following: 

1. Establishing a Prevention Strategy for HIV: Medicated Assisted 

Therapy; Vietnam Situation: An Overview of the HIV Epidemic and 

Response—Kevin P. Mulvey, PHD, Substance Abuse and Mental 

Health Services Administration (SAMHSA) 

2. Substance Abuse Treatment Advisor, PEPFAR-SAMHSA VN: 

Establishing Political Will and Investment in a New 

Prevention/Treatment Option in Vietnam—Dr. Long, Vietnamese 

HIV/AIDS and Control, Ministry of Health, Hanoi Vietnam (TBA) 

3. Medication Assisted Therapy in Vietnam: A Clinical Perspective—Dr. 

Thuy, Le Chan Clinic, Hai Phong 

4. Technical Assistance Demands and Needs in Establishing 

Medication Assisted Therapy—Dr. Nhu To, Family Health International, 

Hanoi Vietnam 

9:00 a.m.–5:30 p.m. 

Astoria 

NIATx OTP Project (invitation only) 

Kimberly Johnson, MBA, University of Wisconsin, Madison, WI 

Lynn Madden, MPA, APT, New Haven, CT 

Tom Zastowny, PhD, Webster, NY 

This session will be the wrap up session for the CSAT funded NIATx 

OTP project. The project is a year-long effort for 30 providers to 

improve access to and retention in treatment. The goal of the day 

will be to celebrate success, share stories and learn some tools and 

techniques for spreading improvements through the agency when 

there are multiple sites and sustaining improvement over time once 

the project is complete. 




It will begin with an overview of the project accomplishments, 

followed by participant presentations. Prior to lunch there will be a 

presentation on spreading change. Following lunch there will be 

more participant presentations and the program will wrap up with a 

final presentation on sustaining improvement. 

9:00: Project Accomplishments: Kim Johnson 

9:30: Participant Presentations: Overcoming our Biggest Barriers 

11:00: Spreading Change through the Agency: Tom Zastowny 

12:00: Lunch 

1:00: Participant Presentations: How I Got the Staff Motivated 

for Change 

2:30: Break 

3:00: Sustaining Change: Lynn Madden 

4:30: Wrap up and Plan for Conference Presentation 

The participant presentation topics are subject to change based on 

the progress of the overall project and their identification of issues 

they would like to hear about from their peers. 




9:30 a.m.–12:00 p.m. 

Boulevard Room 

HIV Testing, Counseling and Treatment in OTPs— 

New Research Findings and Clinical Implications 

Petra Jacobs, MD, Center for the Clinical Trials Network, 

National Institute on Drug Abuse, Bethesda, MD 

Lisa R. Metsch, PhD, University of Miami, Miami, FL 

Katharina Wiest, PhD, CODA, Inc., Portland, OR 

Elinore F. McCance-Katz, MD, University of California at San 

Francisco, San Francisco, CA 

According to estimates from the nation’s new HIV incidence surveillance 

system, there were approximately 56,300 new cases of 

HIV/AIDS diagnosed in the United States in 2006. Moreover, among 

the more than one million people living with HIV in the U.S., approximately 

one-fifth do not know they are infected. Recent studies have 

shown that fewer than half of U.S. drug abuse treatment programs 

are currently offering HIV testing on-site to their patients (Brown Jr. 

et al., 2006; Oser, Tindall, & Leukefeld, 2007; Pollack, D’Aunno, In 

Press; Strauss, Des Jarlais, Astone, & Vassilev, 2003). 

NIDA’s Clinical Trials Network conducted a study to evaluate the 

effectiveness of strategies (referral, on-site rapid testing, on-site 

rapid testing + counseling) to (1) increase HIV testing acceptance 

and receipt of results and (2) decrease HIV sexual risk behaviors. 

The target population was individuals receiving drug abuse treatment 

within community-based drug abuse treatment programs in 

the United States. 2,452 patients were screened in 12 drug abuse 

treatment programs (including three methadone programs) across 

the U.S. to identify patients who had not been HIV tested in the past 

12 months. The screening data indicate that only 28% had been 

tested in the prior year, and one-fifth had never been tested. In this 

session, the main study findings will be presented and their implications 

for OTP practice discussed. 

The last presentation will summarize the issues related to medication-assisted 

treatment and HIV/AIDS. Drug users’ access to antiretroviral 

therapy might be complicated. Additional comorbidities 

might cause poorer outcomes for HIV/AIDS. It is important for the 

healthcare provider to understand and manage the complex drug 

interactions that are clinically significant. The presentation will 

provide a general overview and evidence-based recommendations. 

Sponsored by the National Institute on Drug Abuse, 

the National Drug Abuse Treatment Clinical Trials 

Network (NIDA/CTN). 


1:00 p.m.–5:00 p.m. 

Continental B 

Minimize Liability, Manage Risk, Ensure Patient 

Safety: Effective Strategies in Outpatient 

Methadone Treatment 

Todd Mandell, MD, Vermont ADAP, Burlington, VT 

Lisa Mojer-Torres, JD, New Jersey Division of Addiction 

Services, Lawrenceville, NJ 

Alan Wartenberg, MD, Meadows Edge Recovery Center, North 

Kingstown, RI 

Although the SAMHSA/CSAT Treatment Improvement Plan (TIP) 

43 states that medication-assisted treatment has been effective in 

facilitating many patients’ recovery from opioid addiction for over 

40 years, recent reports of adverse incidents and deaths associated 

with methadone have raised concern among state and national 

legislators about the risks involved. The 2009 General Accountability 

Office Report examined factors contributing to methadoneassociated 

deaths and found that use of methadone for pain 

management increased the drug’s prevalence, contributing to the 

rise in methadone-associated overdose deaths. These deaths and 

other adverse incidents led to a number of lawsuits and proposed 

legislation. 

Research supports the perspective that opioid addiction is a medical 

disorder that can be treated safely and effectively with medications 

when they are administered under conditions consistent with their 

pharmacological efficacy and accompanied by necessary supportive 

services such as psychosocial counseling, treatment for co-occurring 


disorders, medical care and vocational rehabilitation. Physicians, 

psychiatrists, clinical staff, nurses, and opioid treatment program 

directors, providers and staff need to understand how to minimize 

incidents such as patients driving under the influence of multiple 

substances, unsafe diversion of take-home medication, unsafe induction 

and reduction of medication, and dosing practices without 

consideration of clinically assessed severity of dependence and 

metabolism rates. 

This workshop is for healthcare and mental health professionals who 

are involved in the direct care of patients seeking help for opioid 

dependence. Conducted by experts in insurance, law, policy and 

daily clinical practices, this training will provide a framework for 

applying best practices and developing comprehensive risk management 

strategies to improve patient safety and eliminate transfer, 

reduce and manage the risks associated with medication assisted 

treatment for opioid dependence. Participants will have the opportunity 

to ask questions and enter into a dialogue with faculty and each 

other to expand their knowledge of current trends and develop skills 

in identifying and preventing risks. 





1:00 p.m.–5:00 p.m. 

Continental C 

European Opiate Addiction Treatment Association 

(EUROPAD) 

Chairmen: Icro Maremmani, MD (Pisa, Italy, EU) 

Marc Reisinger, MD (Brussels, Belgium, EU) 

1:00 p.m. Opioid maintenance treatment (OMT) and patterns of 

crime reduction during treatment 

Clausen, T. (Oslo, Norway) 

1:15 p.m. Is it possible to provide a democratic treatment in a nondemocratic 

environment 

Dvoryak, S. (Kiev, Ukraine) 

1:30 p.m. Compared analysis of representations of needle exchange 

program in prison in France between inmates, medical 

team and prison staff 

Ferrer-Borras, D., Remy, A., and Sistach, D. (Perpignan, 

France, EU) 

1:45 p.m. Philosophy of treatment and standards of care: the 

Bulgarian way 

Kantchelov, A. (Sofia, Bulgaria, EU) 

2:00 p.m. Treating drug users with co-occurring mental disorders 

Kastelic, A. and Segrec, N. (Ljubljana, Slovenia, EU) 

2:15 p.m. Are methadone and buprenorphine associated with a 

dramatic increase of fatal cardiac arrhyth mias 

Leonardi, C. (Rome, Italy, EU) 

2:30 p.m. Drug users mortality in Slovenia: sociodemographic 

characteristics 

Lovrecic, B. and Semeri, J.S. (Ljubljana, Slovenia, EU) 

2:45 p.m. Mental status of heroin addicts at the beginning of the 

treatment: prevalence of comorbid mental disorder 

Lovrecic, M. (Ljubljana, Slovenia, EU) and Maremmani, I. 

(Pisa, Italy, EU) 

3:00 p.m. Is psychopathology of addiction related to dual diagnosis 

Maremmani, I. and Maremmani A.G.I. (Pisa, Italy, EU) 

3:15 p.m. The effect of psychiatric severity on the outcome of 

methadone maintenance treatment 

Pani, P.P. (Cagliari, Italy, EU) 

3:30 p.m. Treating psychotic patients with agonist opioid therapy 

and atypical antipsychotics 

Pieri, M.C. (Bologna, Italy, EU) 

3:45 p.m. Outcomes of a methadone maintenance program in an 

outpatient treatment setting: daily consump tion versus 

take home treatment 

Somaini, L. (Biella, Italy, EU) 

4:00 p.m. Opiate-related hospitalization and criminality in relation 

to changes of maintenance treatment in Sweden 

Stenbacka, M. and Romelsjö, A. (Stockholm, Sweden, EU) 

4:15 p.m. Minor side-effects during opiate maintenance, major 

nuisance for patient 

Vossenberg, P. (Deventer, Netherlands, EU) 

4:30 p.m. Naltrexone treatment and HIV risk reduction for heroin 

addiction: 10-years Penn/Pavlov expe rience 

Krupitsky, E. (St. Petersburg, Russia) 

4:45 p.m. Hepatitis C prevalence in Hospital outpatients’ unit: 

A 932 persons’ cohort follow up in France 

Courthy, P. (Clermont Ferrand, France, EU) 

In collaboration with EUROPAD-Italia and Italian 

Society of Addiction Medicine (SITD). 

Welcome Reception 


Grand Ballroom 

5:30 p.m.–7:30 p.m. 

The Welcome Reception affords all participants the 

opportunity to make new professional and personal 

acquaintances, as well as to enjoy some relaxing time 

with old friends and colleagues not seen for too long. 

Sponsored in part by Mallinckrodt (a Covidien 

Company) and SAMMS. 


Exhibit and Poster Sessions 

The National Conference serves as a central gathering point for the 

opioid treatment community and offers significant opportunities for 

exhibiting companies and attendees to interact with other professionals 

who are devoted to the treatment of opioid dependence 

throughout the nation and abroad. The registrants will consist of the 

decision makers in this field who spend over $1 billion annually 

treating more than 260,000 patients in opioid treatment programs. 

In order to provide exhibitors with steady exposure to conference 

attendees, all continental breakfasts, refreshment breaks and poster 

sessions will be held exclusively in the exhibit area. An Exhibitors 

Networking Refreshment Event will be held Monday, October 25th 

from 3:00–4:00 p.m. to encourage contact and dialogue between 

opioid treatment professionals and the exhibiting companies. 

Exhibit Hours 

Monday, October 25: 7:30 a.m.–9:30 a.m.; 11:30 a.m.–4:30 p.m. 

Tuesday, October 26: 7:30 a.m.–1:30 p.m. 

Posters are in place at all times when the exhibit hall is open. 

Authors will present their topic on Tuesday from 7:30 a.m.– 

8:45 a.m. 

1A Results from the First Mortality Data Collection 

Effort in Opioid Treatment Programs 

Jane Maxwell, PhD, Gulf Coast Addiction Technology 

Center 

1B Proposed 2010 Mortality Data Collection Form for 

Opioid Treatment Programs 

Jane Maxwell, PhD, Gulf Coast Addiction Technology 

Center 

2 Successful Hepatitis A & B Vaccination Project in 

an Opiate Treatment Program 

Michelle Kletter, BAART 

3 Integration of Methadone Maintained Pregnant 

Women into Residential Care Medication Safety Issues 

Alicia Kletter, NP, BAART Programs FACET 

4 Social Networking Media and OTPs— 

Opportunities to Improve Communication and 

Treatment Outcome 

Trusandra Taylor, MD, JEVS Human Services 

5 Medication Assisted Recovery with Vivitrol for 

Poly-Substance Dependence—Case Series from 

2006–2010 

Punyamurtula Kishore, MD, Fitchburg State College 

6 Massachusetts Home Detoxification Model — 

An Integration of Public Health and Primary Care 

Punyamurtula Kishore, MD, Preventive Medicine 

Associates 

7 Implementation of an Electronic 

Information System 

Lawrence Brown, Jr., MD, Addiction Research and 

Treatment Corporation 

8 30-HIV/AIDS-Related Health Services in 

Substance Abuse Treatment Programs 

Lawrence Brown, Jr., MD, Addiction Research and 

Treatment Corporation 

9 Partnerships—A Vocational Perspective 

Michele Buoninfante, BMIC, Beth Israel Medical Center – 

MMTP 

10 Transformation through Partnerships—Evolution 

of Methadone Maintenance in the 21st Century 

Michele Buoninfante, BMIC, Beth Israel Medical Center – 

MMTP 

11 An Examination of How Abstinence/Moralitybased 

Narratives of Addiction Effect the Treatment 

Decisions of Opiate Addicts 

David Frank, BA, DePaul University 

12 Improving Access to Buprenorphine Services 

Robert Freeman, BS, APT Foundation, Inc. 

13 Comparison of Psychosocial Treatments added 

to Pharmacotherapy with Buprenorphine 

Albert Hasson, MSW, UCLA Integrated Substance Abuse 


14 Mobile Medication Units and Office Based Services 

for Opioid Addicted Clients 

Jude Iheoma, PhD, State of New Jersey, Division of 

Addiction Services 

15 Differences in Retention by Buprenorphine 

Treatment Site 

Albert Hasson, MSW, UCLA Integrated Substance Abuse 


NEW 

for 

2010 

Trivia! 

Please visit the Exhibit Hall and answer questions to enter a drawing for prizes from AATOD 

at the Closing Plenary. See insert in your registration materials for additional information. 


Southwest Hall 

16 Sex and Drug Using Behavior Among HIV + African 

Americans and Hispanics in an MMTP 

James Mitchell, Addiction Research and Treatment 

Corporation 

17 Safe Methadone Induction/Stabilization—A Best 

Practice Approach to Improve Patient Awareness and 

Knowledge 

Judith Prophete, MD, JEVS Human Services 

18 SMS (Social and Health Service)— 

Make the Link Inside Outside! 

Andre Jean Remy, MD, Centre Hospitalier 

19 Needle Exchange in Prison —Two-Thirds of 

the Jailhouse Medical Units Are Ready in France! 

Preliminary Results of the National Harm 

Reduction Survey 

Andre Jean Remy, MD, Centre Hospitalier 

20 Transformation Through Partnerships —Evolution 

of Methadone Maintenance in the 21st Century 

Bonnie Robbins, PhD, Beth Israel Medical Center 

21 Opioid Relapse Rates Among a Sample of New 

Buprenorphine–Medication Assisted Treatment 

Patients—Relationship with Medication Compliance at 

One Year 

Charles Ruetsch, PhD, Health Analytics, LLC 

22 Refusal of Ancillary Support Services Early in 

Opioid Dependence in Opioid Dependence Treatment 

Predicts Six Month Buprenorphine-Medication Assisted 

Treatment Compliance 

Charles Ruetsch, PhD, Health Analytics, LLC 

23 Sublingual Buprenorphine Treatment of Opioid 

Dependence in American Indians 

Anthony Dekker, DO, Indian Health Service 

24 Comparison of a Prescription Based Outpatient 

Buprenorphine Program with a Dispensed 

Buprenorphine Program in a Community Setting 

David Parcher, MA, Kent Sussex Counseling Services 

25 Office-Based Pharmacy-Based Program— 

A Novel Medical Maintenance Model for OAT in New 

York City 

Ann Beeder, MD, Weill Cornell Medical College 

26 Opiate Addiction Treatment Patients and Chronic 

Pain—How Data Can Help Improve Practice 

Erin Stevenson, MSW, University of Kentucky 

27 Methadone Maintenance Outcomes—Quality of 

Life and Patient Self Esteem Examined in Relation to 

Anecdotal Evidence of Patients Desire to Discontinue 

Treatment 

Joseph Stanley, BS, Denver Health Medical Center–OBHS 

28 Prescription Opioid Abuse and other Factors 

Associated with First Time Admission into an Opioid 

Treatment Program 

Andrew Rosenblum, PhD, NDRI 

29 Disaster Planning and Substance Abuse Stigma 

with Respect to Methadone Maintenance Treatment 

Deborah Podus, PhD, UCLA Integrated Substance Abuse 


30 Methadone Maintenance Treatment Patients 

Characterized with High Rate of ADHD and OCD— 

And Low Rate of Pathological Gambling 

Einat Peles, PhD, Adelson Clinic for Drug Abuse 

Treatment and Research 

31 Buprenorphine at Syringe Exchange 

Herman Joseph, PhD, NDRI Consultant 

32 Program Development and Patient Characteristics 

Associated with Overdose Prevention Education and 

Training Within Opioid Dependence Treatment 


Lynn Madden, MPA, The APT Foundation and Yale 

University 

33 Maternal and Neonatal Methadone Issues— 

Who are We Treating 

Maureen Elston, ARNP, Spokane Regional Health District– 

Methadone Program 

34 Opioid Addiction Treatment Modalities In Ukraine 

Natalya Vlasova, MA, NGO STEPS Vinnytsia Branch 

Ukraine–AATOD 

Posters are not approved for Continuing Education Credits. 

Exhibitors Networking 

Refreshment Break 

Monday, October 25, 2010 

3:00 p.m.–4:00 p.m. 

Southwest Hall 

Sponsored in part by: Atlantic Diagnostic 

Laboratories, Kols Containers Inc/OBerk New 

England, Tower Systems, and VistaPharm. 


Conference Sessions 


Monday Continental Breakfast 

7:30 a.m.–8:30 a.m., Southwest Hall 

Sponsored by VistaPharm Inc. 

OPENING PLENARY SESSION 

8:45 a.m.–10:15 a.m. 

International North 

Building Partnerships: 

Advancing Treatment & Recovery 

Susan McKnight, 

MPH, Program 

Coordinator, Lake 

County Health 

Department, 

Waukegan, IL 

Theodora Binion 

Taylor, Director, 

Division of 

Alcoholism and 

Substance Abuse, 

Illinois Depart ment 

of Human Services, 

Chicago, IL 

Mark W. Parrino, 

MPA, President, 

American 

Association for the 

Treatment of 

Opioid Depen - 

dence, Inc., New 

York, NY 

H. Westley Clark, 

MD, JD, CAS, FASM, 

Director, Center for 

Substance Abuse 

Treatment, 

Rockville, MD 

Hon. Danny K. 

Davis, Congress - 

man 7th District, 

House of Repre - 

sentatives, 

Chicago, IL 

The Opening Plenary will focus on the significant challenges facing 

our field in Illinois and the nation. Ms. Susan McKnight will open the 

conference by welcoming attendees to Chicago and will provide an 

overview of the conference. Conferees will also hear from Illinois’ 

Director of the Department of Alcoholism and Substance Abuse 

(DASA), Theodora Binion Taylor and Congressman 7th District, 

House of Representatives, Danny K. Davis, on how the state is 

working to build partnerships to advance treatment and recovery in 

Illinois and the nation. Mr. Mark Parrino, AATOD President, will 

present an overview of the challenges facing opioid treatment 

programs in the United States and AATOD’s initiatives to respond to 

these changing dynamics now and in the future. Dr. Westley Clark, 

Director of Center for Substance Abuse Treatment, will discuss 

federal initiatives to improve treatment access and quality. 

10:30 a.m.–12:00 p.m. 

WORKSHOP SESSIONS 

Workshops will offer a chance to review the latest treatment data 

and health care policies, examine their implications for our patients, 

and strengthen the skills needed to improve the quality of services. 

Basic Track: This year we will again be offering a special 

sequence of workshops designed to act as a refresher for seasoned 

professionals and to meet the needs of individuals who are new to 

this field. Those who attend all six sessions listed will receive a 

special certificate of completion. 

Basic Track Workshop Sessions: A1, B1, C1, D1, E1 and F1 

A1 Methadone 201 

Continental A 

Moderator: Laura McNicholas, MD, Philadelphia VAMC, 


Trusandra Taylor, MD, JEVS Human Services, Philadelphia, PA 

Susan Neshin, MD, JSAS Healthcare Inc., Metuchen, NJ 

J. Thomas Payte, MD, Colonial Management Group, LP, Orlando, FL 

This interactive workshop is designed for the physician/clinician 

who has taken Opioid Maintenance Pharmacotherapy: A Course for 

Clinicians and is now treating patients in an opioid treatment 

program. Reviews of this course showed requests for additional time 

and more advanced information related to opioid addiction treatment. 

A short update on new information and ongoing research 

about methadone will be presented. Topics for discussion may 

include: methadone associated mortality, induction issues, cardiac 

risk assessment/management, drug-drug interactions, benzodiazepines 

and pain management. 

Participants are encouraged to bring interesting/complex cases to 

stimulate questions that will illustrate issues in the successful 

management of patients on methadone maintenance. 

* Note: Basic Track 


A2 Treating Opioid Dependent Pregnant Patients: 

Results of the MOTHER Study 


Hendree Jones, PhD, Research Triangle Institute International, 

RTP, NC 

Karol Kaltenbach, PhD, Thomas Jefferson University, 


This workshop will present neonatal and maternal outcomes of the 

Maternal Opioid Treatment: Human Experimental Research 

(MOTHER) project, a seven-site, international, double-blind 

randomized clinical trial. The presentation will include the comparison 

of methadone and buprenorphine on the primary outcome 

measures: number of neonates requiring NAS treatment; peak NAS 

score; total amount of medication needed to treat NAS; length of 

hospital stay; and head circumference. Key secondary outcomes 


presented will include neonatal and maternal drug use treatment 

and delivery outcomes. The workshop will conclude with a discussion 

of the historical importance and far-reaching clinical practice and 

health-policy implications of these data. 


A3 New York’s Outpatient Transformation: 

Integrated OTP & General Treatment 

Continental B 

Belinda Greenfield, PhD, NYS Office of Alcoholism & Substance 

Abuse Services (OASAS), New York, NY 

Ira Marion, MA, Albert Einstein College of Medicine (AECOM), 

Bronx, NY 

Deborah Egel, Esq., NYS Office of Alcoholism & Substance Abuse 

Services (OASAS), New York, NY 

New York’s “Transforming Out-Patient Services” (TOPS) intends to 

integrate opioid and general addiction treatment offering one 

continuum of outpatient care. Services under this model include 

pharmacological options, behavioral therapy approaches, and 

recovery-oriented / patient-centered care, along with other wrap 

around services, all within a single clinic setting. The historical 

underpinnings of this model and NYS' Methadone Transformation 

efforts will be presented along with the current regulatory, fiscal, 

clinical, and certification challenges, as New York prepares for 

Health Care Reform. TOPS as a new integrated delivery strategy, 

with applicability to accountable care organizations (ACOs) and 

medical homes will also be described together with implications for 

National health care reform initiatives. 




A4 Low-Intensity Treatment Strategies: 

Maximizing Treatment Retention 

International South 

Robert P. Schwartz, MD, Friends Research Institute, Baltimore, MD 

Donald A. Calsyn, PhD, Alcohol and Drug Abuse Institute, 

University of Washington, Seattle, WA 

Shannon Gwin Mitchell, PhD, Friends Research Institute, 

Baltimore, MD 

Decades of research on medicated assisted opioid treatment 

programs (OTPs) have consistently found that patients remaining in 

treatment have superior outcomes in terms of substance use, arrests 

and incarceration, employment and physical health as compared to 

those who leave treatment. Patients leave treatment both voluntarily 

and involuntarily. In this workshop, findings from several studies will 

be presented that provide practical strategies that could be implemented 

in OTPs to reduce both voluntary and involuntary treatment 

terminations. Strategies include interim methadone, alternatives to 

administrative discharge, and strategies to improve tapering 

attempts by stable patients. 


A5 Integrating a Peer to Peer Recovery Oriented 

System of Care (ROSC) into MAT 

Continental C 

Joycelyn Woods, CMA, National Alliance of Medication Assisted 

Recovery, New York, NY 

Walter Ginter, CMA, MARS Project (a NAMA Recovery project), 

Bronx, NY 

OTPs have changed from the early model that included a Peer to 

Peer component and an array of comprehensive services. A Recovery 

Oriented System of Care (ROSC) is a comprehensive array of services 

that are person-centered and a self-directed approach to treatment 

and recovery. Peer to Peer services improve patient self-esteem 

and work in a positive way so patients set goals and see themselves 

as capable. ROSCs build on personal responsibility, patient strength, 

and resilience of individuals, family support and communities to 

achieve sustained health, wellness and recovery. This workshop will 

provide clinics with the tools to understand and identify a ROSC and 

understand the significance of Peer to Peer services. 

1:30 p.m.–3:00 p.m. 

HOT TOPIC ROUNDTABLES 

Hot Topic Roundtables are facilitated discussions that focus on 

current controversial issues in an informal context. Meet with your 

colleagues as you learn, challenge, support and share your views 

with others who may have similar or different opinions, experiences 

or interests. Engage in one or more of these facilitated discussions. 

Experienced leaders in the field will be facilitating these sessions: 

• Methadone and the Prolonged QT Interval 

Continental B 

Facilitator: Craig Showalter, MD 

• US–Mexican Border Issues 

Continental C 

Facilitator: Megan Marx, MPH 

• Cannabis Use in MAT 

Lake Ontario, 8th Floor 

Facilitator: Bettye Harrison 

• Solutions to Administrative 

Lake Michigan, 8th Floor 

Discharge for Financial Reasons 

Facilitator: Walter Ginter, CMA 

• Benzodiazepines & Admission to OTPs Lake Huron, 8th Floor 

Facilitator: Jason Kletter, PhD 

• Methadone Related Drug Deaths 

Lake Erie, 8th Floor 

and Policy Implications 

Facilitator: Ron Jackson, MSW 

1:30 p.m.–3:00 p.m. 


#1 Nutrition in OTP 


Karen Lazarus, MD, Beth Israel Medical Center Methadone 

Maintenance Treatment Program, New York, NY 

Many patients in opioid treatment programs are at risk for nutrition 

related diseases. Identifying and addressing malnutrition or nutritional 

risk enables us to help our patients enhance their health and 




well-being. This also meets The Joint Commission standards for nutritional 

screening and assessment for patients in opioid treatment. 

This workshop will discuss: nutrition screening as per The Joint 

Commission standards; identification of malnutrition; methods of 

nutritional assessment with emphasis on problems commonly seen 

in OTPs; tools for rapid nutritional assessment; guidelines for 

referral; and an overview of healthy eating focusing on healthful 

food recommendations. 


#2 Addressing Smoking Cessation in Opioid 

Treatment Programs 


Shadi Nahvi, MD, Albert Einstein College of Medicine, Bronx, NY 

Michael Stein, MD, Brown University Program in Medicine, 

Providence, RI 

Kimber Richter, PhD, University of Kansas Medical Center, 

Kansas City, KS 

Tobacco is a major cause of excess mortality among persons with 

opioid dependence, yet smoking continues to be under addressed in 

treatment programs. This workshop will provide an overview of the 

problem as well as best practices and strategies for addressing 

tobacco use in opioid treatment programs (OTPs). The workshop will 

present an overview of epidemiology, followed by a discussion of 

evidence-based practices in smoking cessation and the most recent 

data from clinical trials. Several existing models of smoking cessation 

services in OTPs will be discussed, focusing on practical ways to 

incorporate smoking cessation services into existing programs. 





#3 Strategic Alliances—Clinically Effective and 

Cost Efficient Treatment: Six Examples 

Continental A 

Linda Hurley, CAGS, CODAC Behavioral Healthcare, 

Cranston, RI 

Collaborations and partnerships can expand treatment and recovery 

support options for our increasingly challenged population. They can 

be expansive and community-wide, or small and precisely defined. 

Developing a culture of collaboration is critical to accessing, sharing 

and optimizing existing resources. Six varied, successful and practical 

models will offer participants an opportunity to develop a plan 

to increase the quality and scope of their services through collaboration 

and partnerships. In addition to presenting blueprints for 

community partnerships, outcome data and research, the workshop 

will address the need for effective community public relations—the 

foundation for successful community partnering. 


4:00 p.m.–5:30 p.m. 


B1 Meeting the Needs of Patients with 

Co-Occurring Disorders 


Joan E. Zweben, PhD, Executive Director, East Bay Community 

Recovery Project, Oakland, CA 

This workshop will discuss how counselors can help integrate the 

treatment of psychiatric disorders into the opioid treatment 

program. The presenter will discuss addictive behavior and psychiatric 

problems, barriers to addressing them, prioritization of treatment 

tasks and appropriate education for patients. The presenter 

will focus on anxiety disorders (especially PTSD) and mood disorders, 

and also review screening and assessment of suicide risk from 

the perspective of agency protocols as well as the role of the counselor. 

Treatment issues will include psychosocial issues (coping 

strategies, stigma), medication issues (attitudes, feelings, adherence), 

and collaboration with physicians as well as a review of 

several evidence-based treatments. 



B2 Prescription Opioid Addiction Treatment 

Study: Outcomes and Clinical Implications 


Roger D. Weiss, MD, McLean Hospital, Belmont, MA 

Jennifer S. Potter, PhD, University of Texas Health Science 

Center, Department of Psychiatry, San Antonio, TX 

Prescription opioid dependence has become a national public health 

priority; prescription opioids are now comparable to marijuana as 

the most common form of drug initiation. This workshop will present 

the primary and secondary outcomes involving treatment response 

from the NIDA Clinical Trials Network Prescription Opioid Addiction 

Treatment Study—the first multi-site randomized controlled trial to 

specifically examine treatments for individuals with prescription 

opioid dependence, including those with chronic pain. The presenters 

will also discuss the clinical and scientific implications of the 

study results for the treatment of prescription opioid dependence. 


B3 Methadone Safety Best Practices: 

Clinician and Patient Education 

Continental A 

Michele Monroe, Public Health Analyst, SAMHSA, CSAT, 

Rockville, MD 

Laura McNicholas, MD, Philadelphia Veterans Administration 

Medical Center, Philadelphia, PA 

Walter Ginter, CMA, National Alliance for Medication Assisted 

Recovery, Bronx, NY 


This workshop will preview and discuss the upcoming Methadone 

Safety Videos produced by the Substance Abuse and Mental Health 

Services Administration. There are two short videos—one for clinicians 

and one for patients. The workshop panel will lead a discussion 

on engaging patients and clinicians with the videos. The panel will 

also discuss how to promote and educate clinicians and patients on 

best practices for Opioid Treatment Programs. The workshop also 

provides information on how to engage patients in the recovery 

process and how to educate patients on methadone safety. 




B4 Risk Reduction for Illicit Benzodiazepine 

Abuse within an OTP Population 

Continental B 

Dan Johnson, PhD, The Acadia Hospital, Bangor, ME 

This presentation will address benzodiazepine abuse within opioid 

replacement treatment from both a risk management and recoveryoriented 

perspective. Risk reduction and therapeutic engagement 

strategies, and medical interventions to reduce concomitant benzodiazepine 

use among patients will be discussed. From July through 

December 2009, benzodiazepine abuse at Acadia Hospital’s replacement 

therapy programs was reduced by slightly over 30 percent. 

Data from this effort related to patient replacement therapy dose, 

toxicology results, psychiatric treatment needs, overall stability, 

treatment drop rates and perceptions of care will be reviewed at six 

and nine-month intervals. 


B5 Spirituality and Recovery: Exploring the Value 

of the Spiritual Alliance in Recovery 

Continental C 

Alan Lee Nolan, LCSW, Connecticut Counseling Centers, Inc, 

Danbury, CT 

With research highlighting the “therapeutic alliance” as a vital treatment 

component positively impacting a patient’s motivation for 

change, a patient’s relationship, or “recovery alliance” with a “higher 

power” commands clinical attention. Examining evidence regarding 

the potential value of spiritual dimensions of recovery, this workshop 

explores cultivating a person-centered OTP through the utility of 

integrating a patient’s spiritual orientation. The workshop proposes 

a spiritually sensitive recovery archetype, and its effectual assimilation 

with dominant secular treatment models. Partnerships with 

community-based spiritual resources, along with ongoing staff 

competency, quality improvement measures and the use of existing 

data collection processes will be discussed. 

6:00 p.m.–8:00 p.m. 

Digital Access to Medication (D-ATM) Town Hall: 

Using Technology in Opioid Treatment to Prepare 

for Disasters and Promote Continuity of Care 

Continental A 

Arlene Stanton, PhD, SAMHSA/CSAT, Rockville, MD 

Daksha Arora, PhD, Westat, Rockville, MD 

SAMHSA’s D-ATM project (“Digital Access to Medication”) was 

conceived as a technological approach to help ensure OTPs can 

effectively and safely provide medication to patients who have been 

displaced from opioid treatment programs (OTPs) where they are 

normally enrolled. The need for D-ATM was highlighted during the 

attacks of 9-11, but over time, D-ATM has evolved as a valuable tool 

to support continuity of treatment even in the event of more routine 

service discontinuities. Stakeholder input has been critical from Day 

1 and a Steering Committee continues to provide valued input. At 

this point, the system itself has been developed, ‘lessons learned’ 

from a limited pilot have been examined, processes have been 

streamlined and attention has turned to expanding the system into 

OTPs in targeted areas around the country. (More background can 

be found at http://datm.samhsa.gov/.) 

This Town Hall will begin with a brief overview and status report on 

D-ATM. Representatives from “D-ATM OTPs” will describe their 

experiences in implementing the system, including doing so in a 

corporate environment. The Town Hall will also provide the opportunity 

for open discussion of the kinds of disaster preparedness issues 

that OTPs and their patients have encountered in real-life situations, 

whether widespread disasters or more routine service disruptions. 

For instance, how have programs dealt with reimbursement issues or 

differences in dosing practices, when faced with unfamiliar patients 

from other programs What planning is in place for physically 

disabled patients, whether or not D-ATM is in place 

It is hoped this Town Hall will provide one means to continue a 

dialogue among members of the treatment community toward identifying 

which issues still need attention and who can best address 

them. Representatives of CSAT and other Federal and State agencies, 

members of the D-ATM Steering Committee, and program 

directors, patients and staff who have had experience in working 

with D-ATM or in dealing with disaster first-hand, are especially 

encouraged to attend. 




Policy Makers Luncheon 


Supported through a grant from Bendiner & 

Schlesinger Inc. 



Tuesday, October 26, 2010 

Tuesday Continental Breakfast 

7:30 a.m.–8:30 a.m., Southwest Hall 

Sponsored by Reckitt Benckiser 

Pharmaceuticals, Inc. 

MIDDLE PLENARY SESSION 

8:45 a.m.–10:15 a.m. 

Addiction, Pharmacology and the Criminal Justice 

System: What are the Challenges to Expanding the 

Use of Pharmacologic Treatment Interventions for 

Opioid Dependent Individuals Under the 

Jurisdiction of the Criminal Justice System 


Moderator 

Speakers 

Melody Heaps, President 

Emeritus, Treatment 

Alternatives for Safer 

Communities, Chicago, IL 

West Huddleston, 

President, 

National 

Association of 

Drug Court 

Professionals, 

Alexandria, VA 

Scott Chavez, 

Vice President, 

National 

Commission on 

Correctional 

Healthcare, 

Chicago, IL 

Dawn Bushma, 

LCSW, Senior US 

Probation 

Officer, US 

Probation Office, 

Chicago, IL 

This plenary will be moderated by Melody Heaps, President Emeritus, 

Treatment Alternatives for Safer Communities. Despite the fact 

that science has confirmed that addiction is a brain disease and not 

a question of lack of will power or moral failure, certain public 

sectors have been resistant to using medication-assisted treatment. 

In particular, the criminal justice system has resisted, and in some 

cases prohibited the use of such treatment for addicted individuals. 

This plenary will explore the reasons behind such resistance, discuss 

models of pharmacological treatments within the justice system, the 

challenges treatment systems face in working with the criminal 

justice system, and the future of medication-assisted treatment in 

the criminal justice system. 

10:30 a.m.–12:00 p.m. 


C1 Alcohol Abuse in Methadone Treatment: 

Understanding and Addressing a Serious Problem 


Allan J. Cohen, MA, Bay Area Addiction, Research and 

Treatment, Inc. (BAART), Los Angeles, CA 

Daniel D. George, MPH, Matrix Institute on Addictions, Los 

Angeles, CA 

Alcohol abuse in methadone maintained patients has proven to be 

among the most costly and difficult problems to successfully address 

and treat in the opioid treatment program. The costs of this problem 

in terms of patient mortality, poor treatment outcomes, staff and 

program resources and negative community impact are enormous. 

This workshop will present an overview of the problem of alcohol 

abuse in methadone maintained patient populations including a 

review of past and current research on this issue. We will explore an 

array of clinical and programmatic issues related to alcohol abuse 

and discuss treatment options. 



C2 An Analysis of Opioid-Addicted Medicaid 

Patients in Baltimore City 

Continental A 

Gregory C. Warren, MA, Baltimore Substance Abuse Systems, 

Inc., Baltimore, MD 

Utilizing a coordinated public health response, Buprenorphine 

medication and innovative clinical and financial processes have 

been created to improve access and treatment outcomes for heroin 

addicts in Baltimore. There will be three areas of discussion in the 

workshop. First, critical lessons learned in how to establish a 

buprenorphine induction and stabilization continuum of care will be 

discussed. Organizational change and new interagency partnerships 

needed to be forged to address the cultural, regulatory and financial 

barriers which needed to be overcome. Finally, the presenter will 

share Baltimore’s outcomes and preliminary research findings and 

whether these changes achieved savings in health care utilization. 

C3 The Georgia Strategy for Stigma Reduction 

Continental B 

Jonathan Connell, MA, Private Clinic, Albany, GA 

Stacey Pearce, BS, GPA Treatment of Macon, Inc., Macon, GA 

Joelyn Alfred, MS, Opioid Treatment Providers of Georgia, 

Norcross, GA 

For years, treatment providers quietly provided treatment without 

confronting the stigma in our communities. This presentation is 

designed to demonstrate the process Opioid Treatment Providers of 

Georgia went through to confront the stigma within the state of 

Georgia associated with Medication Assisted Treatment. Presenters 


will discuss the collaborative process undertaken in developing the 

video “Exploring the World of Opioid Dependence” and how it is 

presently being utilized in education and stigma reduction efforts. 

In addition, information will be provided on how to develop a 

comprehensive plan for stigma reduction including planning for a 

Methadone Treatment Awareness Day. 

C4 Improving Access and Retention in Treatment 


Kimberly Johnson, MBA, University of Wisconsin, Madison, WI 

This workshop will share results of a year-long project that involved 

30 agencies working together to improve access to and retention in 

treatment using the NIATx model of process improvement. By 

making simple changes like decreasing paperwork, reorganizing 

group times, staffing for intake and accelerating dosing, these 30 

agencies reduced wait times, reduced no shows, improved group 

attendance and increased retention. We will share how they did it 

and discuss opportunities for programs that may be interested in 

participating in a future learning collaborative. 

C5 Partnering with Patients: Developing an 

Effective Peer Mentoring Program 

Continental C 

Robert C. Lambert, MA, Program Director, Connecticut 

Counseling Centers, Inc., Norwalk, CT 

Kurt Kemmling, CMA, Director/Founder, CT Chapter National 

Alliance Medication Assisted Recovery (NAMA), Danbury, CT 

This workshop will focus on the development, implementation and 

integration of peer mentoring services within a methadone treatment 

program, with a specific focus on strengthening the therapeutic 

alliance between the patient and the program. Potential 

benefits relating to patient outcomes and staff utilization management 

will be discussed. The presenters will focus on providing information 

the workshop participants will need to replicate all or part of 

the initiative at their own programs. One key area of focus will be the 

development and implementation of a training curriculum for the 

peer mentors including a specific focus on co-occurring disorders. 

1:30 p.m.–3:00 p.m. 


D1 Overdose Prevention and Treatment in 

Opioid Treatment Programs 


Alexander Walley, MD, Boston University School of Medicine, 

Boston, MA 

Melinda M. Campopiano, MD, UPMC Mercy Family Medicine 

Residency Program, Pittsburgh, PA 

Maya Doe-Simkins, MPH, Boston Medical Center, Boston, MA 

Overdose is a significant public health concern. Unintentional 

poisoning was second only to motor vehicle injuries as causes of 

unintentional injury deaths in 2006. A CDC report showed that 

opioid analgesics were involved in almost 40% of all poisoning deaths 

in 2006. Recent data from opioid treatment programs (OTPs) suggest 

that overdose is an important factor in mortality of patients in treatment. 

Evidence suggests that overdose prevention programs are 

feasible and effective. OTPs are in an important position to implement 

overdose prevention programs. This workshop is designed to 

improve knowledge about opioid overdose, including risk factors, 

prevention, identification and management. 

*Note: Basic Track 





D2 Buprenorphine Pilot Project with Parolees in IL 

Continental A 

Dona Howell, CRADC, Illinois Department of Corrections, 

Marion, IL 

Janelle Prueter, CRADC, TASC, Chicago, IL 

Arturo Valdez, CSADC, Heritage Alternative Systems, 

Chicago, IL 

Illinois’ Sheridan Correctional Center Project has gained national 

attention for its comprehensive approach to reducing recidivism 

among drug-involved offenders. Sheridan parolees were 15% less 

likely to be rearrested for a new crime and 40% less likely to return 

to prison for a new crime or technical violation. 

Success rates for parolees with a history of opiate dependence have 

lagged behind those for the population as a whole. To address this 

disparity in outcomes, the Illinois Department of Corrections and its 

partners are implementing a pilot project that will integrate medication-assisted 

treatment into the continuum of care for parolees. 

D3 National Drug and Alcohol Policy: 

2010 and Beyond 


Paul Samuels, JD, Legal Action Center, New York, NY 

Gabrielle de la Gueronniere, JD, Legal Action Center, 

Washington, DC 

Dan Belnap, JD, Legal Action Center, Washington, DC 

Now is a time of tremendous opportunity for improving the federal 

response to drug and alcohol addiction. The federal healthcare 

reform law has strong coverage for addiction treatment. New pro - 

grams and proposals at key federal agencies have the potential to 

significantly impact the treatment delivery system, and increased 

coverage for critical drug and alcohol-related services means more 

people in need of treatment will be able to access it. This workshop 

will discuss these federal developments for addiction treatment, what 

it means for medication-assisted treatment specifically, and the 

opportunities available for improving federal policy moving forward. 


Awards Program 

International Luncheon 


Supported through grants from Colonial 

Management Group, LP, and Bollinger, Inc. 

D4 MAT for Older Adults: Specialized 

Strategies to Meet Unique Needs 

Continental B 

Fran Schnadig, LCSW, PEER Services, Inc., Evanston, IL 

Katrina Humphreys, LSW, PEER Services, Inc., Evanston, IL 

Older adults who are addicted to drugs are being recognized 

as an at-risk, under-identified and under-served population. 

MAT programs are working to identify new strategies to meet 

the unique treatment requirements of this ever-increasing 

population. 

In responding to these needs, PEER Services has developed 

an evidence-based addiction treatment model which 

addresses: 

• Unique stressors and losses of this population 

• Helping older adults increase positive self-caretaking 

behaviors 

• Communication problems and solutions for older adults 

and their families 

• The specialized, evidence-based psychosocial treatment 

approach needed to meet the needs of older adult 

patients—individual and group treatment modalities 

D5 Partnership with the Patient: 

Key Interventions to Enhance Recovery 

Continental C 

Alexander Kantchelov, MD, The Kantchelov Clinic, Sofia, 

Bulgaria 

Tsvetana Stoykova, MA, The Kantchelov Clinic, Sofia, 

Bulgaria 

Alexander Belchev, MD, The Kantchelov Clinic, Sofia, 

Bulgaria 

Partnership with patients is seen as a basic philosophy, a 

style of interaction, and an essential position and attitude of 

staff and institution. This workshop provides a model for 

specific interventions, implemented at key points in the 

process of treatment-assisted recovery. Ways to develop partnership 

at different levels—assessment and case formulation, 

engaging the patient in a collaborative effort toward 

change, participation in the therapeutic process, defining 

and working together to achieve shared treatment goals— 

are explored. The traditional TTT concept (Treatment– 

Therapy–Techniques) has evolved to promote a new model— 

PPP (Partnership–Progress–Process of Recovery). 

Pre-Banquet Cocktail Reception 


Supported through a grant from CRC Health Group 


7:00 p.m.–9:30 p.m. 

Introduction to the 

Awards Program 


Please join us for the centerpiece of our Conference, a moving tribute to 

those individuals who have been nominated and selected by their peers 

for extraordinary service in the opioid treatment community. These 

successful Award recipients have devoted themselves to improving the 

lives of patients in our treatment system. Dr. Vincent Dole and Dr. Marie 

Nyswander were the first recipients of this Award in 1983. The Association 

has been responsible for bestowing this honor since the first 

Regional Conference of 1984 in New York. 

The Nyswander/Dole “Marie” Awards will be presented by Mary Jeanne 

Kreek, MD. 

Mary Jeanne Kreek, MD, is a graduate of Wellesley College 

and of the Columbia University College of Physicians & 

Surgeons. She is Professor and Head of the Laboratory of 

the Biology of Addictive Diseases at The Rockefeller 

University. Dr. Kreek went to The Rockefeller Institute in 

1964 to join the late Professor Vincent P. Dole; at that same time, Dr. Dole 

was joined by the late Dr. Marie Nyswander. The team of three performed 

the initial studies of the potential use of a long-acting opioid agonist, 

methadone, in chronic management of heroin addiction. She is Principal 

Investigator of an NIH-NIDA P-60 Research Center and author of over 400 

scientific reports. By molecular, cell biological, neurochemical, behavioral 

and basic clinical research and human genetics studies, she has 

documented the role of the endogenous opioid system in cocaine, 

alcohol, and heroin addiction. Dr. Kreek received the AMERSA Betty 

Ford Award in 1996, the ASAM R. Brinkley Smithers Distinguished Scientist 

Award in 1999, the CPDD Nathan B. Eddy Memorial Award for Lifetime 

Excellence in Drug Abuse Research in 1999, and the CPDD Marian 

W. Fischman Award and Lecture in 2005. Dr. Kreek was conferred with 

honorary doctorates from Uppsala University, Sweden, in 2000, the 

University of Tel Aviv in 2007, and the University of Bologna in 2010. 

The 2010 American Association for the Treatment of Opioid Dependence 

National Conference recognizes outstanding contributions to 

opioid treatment by honoring the following individuals with the 

Nyswander/Dole Award. 

Miriam Ochshorn Adelson, MD 

Nevada 

Dr. Adelson’s medication-assisted treatment experience 

began in 1986 when she was sent by the Ministry of 

Health in Israel to work with Dr. Mary Jeanne Kreek in 

New York. In 1993, she founded a substance abuse treatment 

and research clinic in Israel that provides 

methadone maintenance treatment, and in 2000, she 

opened a clinic in Las Vegas, Nevada. Dr. Adelson’s Las Vegas clinic is an 

outstanding research and treatment clinic that provides care and 

continues her long history of research concerning medication-assisted 

treatment. She continues to perform research, including treatment 

outcome evaluation studies, studies of relationship of methadone dose 

18

with serum levels, and collaborative research studies of human molecular 

genetics related to opioid addiction and treatment. 

Lawrence S. Brown, Jr., MD 

New York 

Dr. Brown’s professional career is rooted at Addiction 

Research and Treatment Corporation based in 

Brooklyn, where he remains a champion of comprehensive 

treatment of opioid addiction. He did pioneering 

work in pharmacotherapy interventions such as LAAM 

and Buprenorphine and was at the vanguard of introducing 

HIV treatment and prevention into ARTC’s opioid treatment 

programs. He spent two terms as President of the American Society of 

Addiction Medicine and is a powerful advocate of pharmacotherapy in 

the treatment of addiction. Dr. Brown freely shares his expertise with 

treatment providers and with regulators at the state and federal level. 

He is as willing to listen as he is to offer his own view, always focusing on 

what is best for the patient. 

Gregory Carlson 

Minnesota 

In over 40 years as a medication-assisted treatment 

professional, Mr. Carlson has worked to set the standard 

for patient-oriented care in a field where much has 

changed. He began collecting and using data 

to determine how it influenced patient care in 1973 

when this was not the standard of care. Through direct 

patient care, managing medication-assisted treatment programs, 

educating clinical and other staff at programs, and research, Mr. Carlson 

has demonstrated his commitment to the field. His level of dedication 

has elevated him to be the go-to person in Minnesota for methadone 

related issues, providing assistance to new programs, local communities 

and regulatory agency staff. He believes care should be about the 

patients and everyone should work towards that goal. 

Sergey Dvoryak, MD 

Ukraine 

In 1999, Dr. Dvoryak became a Hubert H. Humphrey 

Drug Abuse Research Fellow at Johns Hopkins University 

in Maryland. This opportunity led Dr. Dvoryak to a 

perspective of substance abuse as a public health issue, 

which should be prioritized in accordance with its 

impact on society. Upon his return to his native 

Ukraine, Dr. Dvoryak worked to start both buprenorphine 

treatment and methadone treatment to address the growing 

opioid use problem. He is currently working to create a system of monitoring 

and evaluation of substance abuse treatment in the Ukraine, 

while providing education to other professionals about the importance 

of substance abuse treatment to public health. 

Penny Hall, RPh 

Georgia 

During her years as a retail pharmacist, Ms. Hall came 

to see addiction from a different perspective before she 

began to work in the field. She witnessed countless 

patients receive addictive medication 

that might not have been necessary. Answering an ad 

for a part-time pharmacist she was exposed to 

methadone treatment, inspiring her to become a Sponsor of her own 

clinic in 1991. During her work in the field, Penny was one of the 

founders of the Georgia methadone providers group, was the first 

AATOD delegate for the state of Georgia, has worked to mitigate the 

Georgia Board of Pharmacy’s restrictive regulations on narcotic treatment 

programs, and was the impetus behind the creation of Methadone 

Treatment Awareness Day in the Georgia House of Representatives. 

Roland C. Lamb, MAOM 

Pennsylvania 

Throughout his career as a provider, administrator and 

current Director of the Office of Addiction Services in 

Philadelphia, Mr. Lamb has remained an outspoken 

advocate for medication-assisted treatment. He 

continues to wage a campaign to address community 

opposition and stigma to opioid treatment. He 

supported, advocated for and funded a program that allows the 

methadone maintained person to continue in treatment while incarcerated 

in the Philadelphia Prison System. Mr. Lamb also encourages 

patients to become more active in their treatment and develop self advocacy 

skills to influence public policy. He also formed a Collaborative 

comprised of medication-assisted treatment providers, regulators and 

other government officials to improve communication and standards of 

care within medication-assisted treatment. 

Peter William Lee, MA 

Vermont 

Mr. Lee was Vermont’s first state employee to begin 

publicly advocating for medication-assisted treatment 

in the mid 1990s. At that time, this position was 

strongly opposed by his superiors and the highest 

ranking elected officials. At some risk to his career in 

state government, he assisted in organizing proponents 

of methadone treatment and began educating Legislators and others 

regarding the benefits of this treatment. In 2002, Mr. Lee was successful 

and Vermont’s first methadone clinic opened. Since that time, Mr. Lee 

has worked to grow the number of clinics to five throughout the state. 

Mr. Lee has also been invaluable in increasing the number of physicians 

who are trained to provide office-based opioid treatment utilizing 

buprenorphine. 

John J. McCarthy, MD 

California 

During his 30 years in the addiction field, Dr. McCarthy 

has remained dedicated to providing quality treatment 

in a supportive and respectful manner. He is appreciated 

for his passionate advocacy for methadone 

patients and his commitment to integrating psychiatric 

and other medical care into treatment. Dr. McCarthy 

works to educate other professionals, is a practicing 

psychiatrist, a researcher and a member of numerous advisory committees. 

As a clinician-researcher, he understands the importance of using 

data to improve care and has conducted numerous studies at his own 

clinic without external funding. During presentations he is able to speak 

to audiences with a wide range of educational background and has 

worked hard to change public policy from a punitive to a public health 

model. 

19

Theodora Binion Taylor, ThD 

Illinois 

As a regulatory official, Dr. Binion Taylor has made 

great strides in integrating substance abuse, mental 

health, domestic violence, HIV/AIDS services, and child 

welfare throughout treatment services in Illinois. She 

increased technology utilization throughout Illinois’ 

treatment system to boost access to care and capture 

treatment outcome data. Dr. Binion Taylor supports 

training to assist providers in implementing evidence based treatment 

practices to enhance the quality of care for patients throughout Illinois. 

She is also a compassionate advocate for medication-assisted treatment 

and has fought tirelessly to reduce stigma and educate state leaders 

about the effectiveness of this treatment modality. During the past two 

years, Dr. Binion Taylor has successfully ensured medication-assisted 

treatment funding remains available, despite political pressure to 

reduce it. 

Friend of the Field Award 

Presented by Mark W. Parrino, MPA, AATOD President 

The prestigious Friend of the Field Award was established 

by the American Association for the Treatment of 

Opioid Dependence, Inc. Board of Directors. This award 

recognizes extraordinary contributions to the field of 

opioid treatment by an individual or institution whose 

work, although not directly related to methadone treatment, 

has had a significant impact on our field. The 2010 

Friend of the Field Award has been awarded to: 

C. West Huddleston 

C. “West” Huddleston III, is the Chief Executive Officer 

of the National Association of Drug Court Professionals 

(NADCP). Prior to being appointed CEO, Mr. Huddleston 

served as the first Deputy Director and then Director of 

the National Drug Court Institute (NDCI) for nine years. 

During his 11 years of service at NADCP, Mr. Huddleston has delivered 

over 350 keynote speeches in 44 states and eight countries; authored 16 

publications and briefs; developed and delivered 11 national training 

curricula; briefed numerous state legislatures, testified before U.S. 

Congress, and international Parliaments; and has been interviewed 

repeatedly by radio, television, and print media on topics related to 

alternative justice, alcohol and other drug abuse/dependence, drug 

policy, crime and public safety. Mr. Huddleston is regarded as a pioneer 

in drug courts and other alternative sentencing strategies having spent 

more than a decade providing vision and leadership throughout 

the world. 

Prior to his work at NADCP/NDCI, Mr. Huddleston worked for eight years 

as a board licensed clinician with misdemeanor and felony offenders at 

the county, state and federal levels. During this period, Mr. Huddleston 

worked throughout the Tennessee and Oklahoma justice systems to 

develop, implement and operate numerous offender-specific, in-custody 

and community mental health and substance abuse treatment pro - 

grams. Mr. Huddleston served as the director of two community corrections 

programs and as the interim director of a 125-bed pre-release 

correctional center. 

Mr. Huddleston serves as an advisor and/or consultant to the U.S. 

Department of Justice (DOJ), U.S. Department of Transportation (DOT), 

U.S. Department of Health and Human Services (HHS), Drug Enforcement 

Administration (DEA), White House Office of National Drug 

Control Policy (ONDCP), United Nations Office of Drugs and Crime 

(UNODC), the Organization of American States (OAS) and as a distinguished 

faculty member of the National Judicial College. 

Richard Lane/Robert Holden Patient Advocacy Award 

Presented by Joycelyn Woods, MA and Walter Ginter, CMA 

Richard Lane was a long-term heroin user 

who, upon release from prison in 1967, 

was instrumental in establishing one of 

the Nation’s first methadone treatment 

programs. In 1974, he became the Executive 

Director of Man Alive and later served 

as Vice President of the American Methadone Treatment Association 

and as Vice Chairman of the Governor’s Council on Alcohol and Drug 

Abuse in Maryland. Mr. Lane was a passionate advocate for methadone 

treatment and, by disclosing his own treatment experiences, provided 

inspiration to patients and colleagues alike. 

Robert Holden was also a recovering heroin user, who later became the 

Director of PIDARC, an outpatient methadone treatment program in the 

District of Columbia. He later served as the Vice President of the American 

Association for the Treatment of Opioid Dependence, succeeding 

Richard Lane’s term of office. This award was established in 1995 and 

recognizes extraordinary achievements in patient advocacy. 

Lisa Mojer-Torres, JD 

Ms. Torres’ contributions, in her community and nationally, 

have had an immense impact on awareness of 

medication-assisted treatment and recovery. She is a 

tireless advocate for the dignity and rights of people 

seeking care and in long-term recovery from addiction 

herself. Ms. Torres is currently the Consumer and 

Recovery Advocate for New Jersey’s Division of Addiction Services and 

through this position works to bring the voices of people receiving services 

into all aspects of the Division’s activities. She has developed and 

presented trainings to the public that integrate her personal recovery 

experiences with the need for transformation of systems of care 

centered on the rights and needs of individuals. She sits on many 

recovery oriented committees, boards, and has held multiple national 

advisory board positions. 

The 2010 Awards Banquet 


Supported through a grant from 

Mallinckrodt (a Covidien Company). 

20


Wednesday, October 27, 2010 

Wednesday Continental Breakfast 

7:00 a.m.–8:00 a.m. 

Continental Ballroom Foyer 


8:00 a.m.–9:30 a.m. 

E1 Building Effective Therapeutic Partnerships 

Within Opioid Agonist Treatment 

Continental A 

Robert C. Lambert, MA, Program Director, Connecticut 

Counseling Centers, Inc., Norwalk, CT 

Research indicates that the quality of the therapeutic relationship 

has a greater effect on patient retention and outcomes then the 

specific counseling approach used. This “basic track” workshop will 

focus on the essential fundamental counseling skill of forming and 

maintaining the therapeutic relationship and the unique challenges 

involved in enhancing the therapeutic alliance with medicationassisted 

patients within the clinical setting. A key area of focus will 

be counselor expectancy as a therapeutic factor. Boundary issues 

specific to the counselor in recovery will also be explored. The 

presenters will discuss methods to enhance the quality of the therapeutic 

alliance. 


E2 Using Data From the REMAS Study to Assist 

Counselors in Promoting Sexual Risk Reduction 

Continental B 

Donald Calsyn, PhD, Alcohol & Drug Abuse Institute, University 

of Washington, Seattle, WA 

Robert Sterling, PhD, Jefferson Medical College, Thomas 

Jefferson University, Philadelphia, PA 

Stephen Weinstein, PhD, Jefferson Medical College, Thomas 

Jefferson University, Philadelphia, PA 

Findings from the Real Men Are Safe (REMAS) study will be 

presented with an emphasis on results concerning engaging in sex 

under the influence of drugs or alcohol. Suggestions about how findings 

from REMAS can be integrated into counseling sessions will be 

presented. Despite the REMAS intervention being associated with 

sexual risk reduction and identified by the CDC as a promising 

evidenced based HIV prevention intervention, few programs are 

using REMAS materials. 

Possible reasons for low adoption will be proposed and attendees 

will be led in a discussion of what would be needed to increase adoption 

of REMAS. 

E3 PCSS-Mentoring Network for OTPs: Safe Use 

of Methadone and Buprenorphine 


Andrew Saxon, MD, University of Washington, Seattle, WA 

Gavin Bart, MD, Director of the Division of Addiction Medicine 

at Hennepin County Medical Center, Minneapolis, MN 

Trusandra Taylor, MD, Medical Director, JEVS Human Services, 


This workshop describes the Physician Clinical Support Systems 

(PCSS) for Buprenorphine and Methadone, two related 

SAMHSA/CSAT funded networks of mentors who provide education 

and support to clinicians prescribing buprenorphine and/or 

methadone. The workshop offers an overview of the PCSS, describes 

its website, guidances and other resources, and discusses the policy 

implications of this peer education strategy for OTPs and beyond. 





E4 Can You Watch My Kids While I Get Medicated 

Removing Barriers to Treatment 

Continental C 

Jeneane Burke, MSN, Thomas Jefferson University, 


Colleen Maguire, MHS, Thomas Jefferson University, 


The majority of female patients receiving MAT are single mothers 

with few supports. Lack of safe childcare is a major barrier to 

entering, engaging and/or remaining in treatment. The presenters 

will share evidence on the need for childcare during MAT, benefits of 

an on-site service and elements of Women’s Centered Treatment. 

They will describe their clinic’s Parent Child Center (PCC): staffing, 

funding, infection control measures, developmentally appropriate 

programming, assessment/referral of at risk children, communication 

from PCC to the treatment team, acclimation of children to the 

PCC and how the PCC is linked into the parents’ treatment program. 

E5 Innovative Group Treatment in an Outpatient 

Opioid Replacement Therapy 


Elizabeth Bredin, LICSW, Program Director, Bay Cove Treatment 

Center, Boston, MA 

Julia Carlson, LICSW, Senior Clinician, Bay Cove Treatment 

Center, Boston, MA 

The Bay Cove Treatment Center is a clinically-oriented methadone 

program treating dual-diagnosed patients. The treatment contract 

includes one individual and at least one group session weekly, daily 


methadone dosing, and random bi-weekly swabs. Focusing on short 

term, goal-oriented 12-16 week groups, we redesigned the program 

to achieve the following goals: 

• Increase group attendance and cohesiveness 

• Promote measurable life skills 

• Match group experience to specific patient needs 

• Decrease relapse 

• Introduce self-assessment form on group experience to evaluate 

positive behavioral change and increased life skills 

9:45 a.m.–11:15 a.m. 

F1 Linking Patients with Communities of Recovery 


Stephen Gumbley, MA, Co-Director, New England ATTC, 

Providence, RI 

Walter Ginter, CMA, Medication-Assisted Recovery Services 

Project (MARS), Bronx, NY 

Dona Dmitrovic, MHS, Assistant Director, The RASE Project, 

Harrisburg, PA 

Faces & Voices of Recovery presents this workshop where you will 

learn how to articulate a definition of recovery and medicationassisted 

recovery and how to apply recovery management principles 

for people using medication in their recovery. It is very important to 

link patients with critical recovery support services and you will 

learn about the successes and challenges in developing effective 

recovery models. Find out about the ways that your program can help 

your patients connect with communities of recovery using the experiences 

of the MARS and RASE projects that assist people using 

methadone and suboxone in their recovery. 


F2 Why is the Role of the Professional Nurse 

ESSENTIAL in Addiction Treatment 


Deborah Egel, JD, Office of Alcoholism and Substance Abuse 

Services, New York, NY 

Carolyn Drennan, MA, Beth Israel Medical Center-MMTP, New 

York, NY 

Colleen Corte, PhD, University of Illinois at Chicago, College of 

Nursing, Chicago, IL 

Nurses care for individuals across the lifespan and across the 

continuum of health care settings. All professional nurses, regardless 

of specialty are needed for the prevention, treatment, and rehabilitation 

critical in meeting the goal of reducing substance use and 

its related health and social consequences. This presentation will 

discuss the importance of addiction nursing to providers, how New 

York has valued their nurses and created the Nurse Advisory Panel, 

and how a specific program has defined the nursing role as essential 

and the resulting benefits for the Opioid Treatment Program 

patients. 

F3 Are You Ready—Really Special 

Considerations for Opioid Treatment Providers— 

Preparing Now for the Next Disaster 

Continental A 

Roye Brown, Program Sponsor and Administrative Director, 

Choices of Louisiana, Inc., Alexandria, LA 

Nicholas Reuter, MPH, Senior Public Health Advisor, 

SAMHSA/CSAT/DPT, Rockville, MD 

Brian McKernan, Technical Assistance Manager, SAMHSA’s 

DTAC (Disaster Technical Assistance Center), Clinton 

Township, MI 

Disasters—widespread or local, man-made or natural—can be especially 

catastrophic for opioid treatment programs (OTPs) and other 

providers. OTPs have additional responsibilities to ensure patient 

health and safety by doing all possible to help patients’ uninterrupted 

treatment. This workshop will provide an overview of behavioral 

health and opioid treatment—specific issues related to 

disaster preparedness; and information on the resources and tools 

available now to help OTPs ensure they are as “disaster-ready as 

possible.” Presenters will challenge OTPs to assess their preparedness 

for the next unexpected event, from terrorist attacks to 

influenza pandemics. 




F4 Clinical Supervisors in Opioid Treatment 

Settings: What are Their Needs 

Continental B 

Monica A. Joseph, PhD, Addiction Research and Treatment 

Corporation, Brooklyn, NY 

Virginia Lambert, LCSW-R, Addiction Research and Treatment 

Corporation, Brooklyn, NY 

Supervisors who are experiencing high levels of job strain may also 

be having difficulty carrying out expected job functions including 

clinical supervision. Without targeted clinical supervision, direct 

care practitioners’ professional skills development and patients’ 

treatment outcomes can be impacted. While job redesign might not 

be an option, enhancing supervisory expertise through the adoption 

of formal supervisory models may decrease perceived job stress. This 

workshop examines the systematic application of Stoltenberg, 

McNeil and Delworth’s Integrated Developmental Model of clinical 

supervision to assess, guide, challenge and support clinical supervisors 

across the three stages of professional counselor development. 

Perceived supervisory effectiveness is also assessed. 


F5 Using Patient Chart Audits to Improve 

Counselor Performance and Enhance Patient Care 

Continental C 

Nancy Aiken, PhD, CHANA, Baltimore, MD 

Meg Stoltzfus, LCPC, REACH Mobile Health Services, Baltimore, 

MD 

As part of the quality assurance measures at R.E.A.C.H. Mobile 

Health Services, a program of the Institutes for Behavior Resources, 

Inc., over 20 quarterly patient chart audits were conducted during a 

span of five years. This presentation, designed for clinical supervisors, 

program directors and staff involved in quality assurance procedures 

will include: 

• Discussion on how to develop minimal standards for patient chart 

audits, 

• Guidance for evaluation of competencies consistent with a staff 

development program, and 

• Examples of how audits can be utilized to guide allocation of 

training resources for clinical and medical staff. 

CLOSING PLENARY SESSION 

11:30 a.m.–12:45 p.m. 

The Partnership of the Field and the Federal 

Government: The Expansion of Healthcare Reform 

and Access to Quality Care 

AATOD is pleased to welcome State Senator Mattie Hunter, 3rd 

District. Senator Hunter has a Masters Degree in Sociology and is a 

certified alcohol and drug counselor and prevention specialist. She 

offers a unique perspective on the relationship of government and 

the treatment community having been a treatment provider at the 

Human Resources Development Institute in Chicago for 18 years and 

a State Senator since 2003. Senator Hunter serves on the Public 

Health Committee and is Co-Chair of the Health Policy Task Force. 

AATOD is also pleased to welcome Dr. Wilson Compton, Director, 

Division of Epidemiology, Services and Prevention Research, 

National Institute on Drug Abuse (NIDA) to wrap up the 2010 

Conference in Chicago. Dr. Wilson Compton is the former Medical 

Director of Addiction Services at Barnes-Jewish Hospital in St. 

Louis, MO. Dr. Compton is the author of numerous articles and 

manuals, and the recipient of numerous grants and awards from the 

field. Dr. Compton has worked diligently for new drug therapies, 

healthcare reform, and the expansion of access to treatment. He will 

discuss the implementation of health care reform and the integration 

of treatment services and primary health care. 

Clinic Tours 

1:00 p.m.–3:30 p.m. 

Visit the Hospitality Table for more information and 

to sign up. 


Speakers: 

Susan McKnight, 

MPH, Program 

Coordinator, Lake 

County Health 

Department, 

Waukegan, IL 

Theodora Binion 

Taylor, Director, 

Illinois 

Department of 

Human Services, 

Division of 

Alcoholism and 

Substance Abuse, 

Chicago, IL 

Senator Mattie 

Hunter, Illinois 

State Senate, 3rd 

District, Chicago, 

IL 

Wilson Compton, 

MD, MPE, 

Director, Division 

of Epidemiology, 

Services and 

Prevention 

Research, 

National Institute 

on Drug Abuse 

(NIDA), Rockville, 

MD 

Mark W. Parrino, 

MPA, President, 

American 

Association for 

the Treatment of 

Opioid 

Dependence, Inc., 

New York, NY 


Conference Notes 

• Smoking is prohibited at all conference events. 

• Your conference badge is your admission to all events and 

educational sessions. Please be sure to wear your badge to 

all conference functions. 

• Participation in this conference assumes knowledge and 

authorization of audio and/or video recordings of portions 

of this conference. 

• Part of the proceeds of the sleeping room rates will be 

used to defray conference expenses. 

• Please take the time to complete all evaluation forms. 

Your feedback is extremely important to the presenters 

and AATOD. 

AUDIO TAPING INFORMATION 

Don’t Miss A Single Important Word! 

As a special service to attendees, the presentations 

will be available on Audio CD. 

With scheduling conflicts and concurrent sessions, Job 

Conference will make it possible to attend every important 

session via audio CD, using advanced techniques assuring 

the highest quality recordings. 

High-speed duplication equipment eliminates long delays, 

allowing you to hear the important information shortly after 

each session has concluded. The CDs provide an excellent 

HILTON CHICAGO 

LOBBY LEVEL 

DOWN TO EXHIBIT HALL 


ecap and a valuable training tool to those who could not 

attend. 

Look for the Job Conference order desk located in the 

registration area and take your information home with you, 

or place an order through the mail after the conference. 

Please refer to your registration packet for a complete 

listing of available sessions. 

Job Conference 

Phone: 1-888-609-TAPE 

Email: Job_CRS@att.net 

CONTINUING MEDICAL EDUCATION (CME)/ 

CONTINUING EDUCATION HOURS (CEHs) 

The 2010 AATOD National Conference will award Continuing 

Medical Education (CME) and Continuing Education 

Hours (CEHs). Please see inside back cover for specific 

information. 

To apply for CMEs/CEHs, conference attendees must pay 

the associated fee, either in advance or at the conference 

registration desk. Attendance at conference events will 

be verified electronically. Each attendee seeking CMEs/ 

CEHs will have a bar code attached to his/her conference 

HILTON CHICAGO 

SECOND FLOOR 


Conference Notes 

badge. At the end of EACH approved session, attendees 

must have the bar codes on their badges “scanned” by 

room monitors in order to record CME/CEH. 

These monitors will have electronic equipment that will automatically 

record each individual’s attendance in a database. 

The database will track and tabulate each attendee’s CMEs / 

CEHs. After the conference, certificates documenting attendance 

and the number of CMEs/CEHs earned will be electronically 

generated and mailed to all eligible attendees. 

Attendees participating in ALL six Basic Track workshops 

will receive an additional certificate documenting their 

participation in this special training series. 

Questions about CMEs/CEHs can be answered by staff at 

the Conference CME/CEH Desk located in the registration 

area. 

A SPECIAL NOTE FOR THE DISABLED 

The American Association for the Treatment of Opioid 

Dependence, Inc. has taken steps required to ensure that 

no individual with a disability is excluded, denied services, 

segregated or otherwise treated differently than other 

individuals because of the absence of auxiliary aids and 

services, as outlined in the Americans with Disabilities Act. 

HILTON 

CHICAGO 

THIRD 

FLOOR 

HILTON 

CHICAGO 

EIGHTH 

FLOOR 


Sweet Home Chicago 

“C’mon, Oh baby don’t you want to go 

Oh c’mon, oh baby don’t you want to go 

Back to that same old place.” —Blues Brothers 

No truer words can be said about this fantastic city—a town 

rich in diversity and cultural activities, a truly international 

city. While attending the Conference, it is highly recommended 

that you squeeze in time to enjoy some of the many 

sites and sounds of the host city. 

Chicago can be unpredictable 

weather wise in late October (it could be warm, brisk 

autumn like, or freezing!), so luckily there are plenty of 

things to do indoors as well as outdoors. No visit to Chitown 

can be complete without an exploration of some of its 

physical beauty. Please take a walk or jog along its lengthy 

lakefront trail path, which is just a few blocks away from 

the Hilton Chicago and witness the unique architecture that 

is abundant across the city. Grant Park and Millennium 

Park are within walking distance from the Conference— 

both bordered by Michigan Ave and the Lakefront. In addition 

to our Hospitality table (which will be present at the 

Conference to assist with providing you helpful information 

about the city), the Chicago Cultural Center and the 

Chicago Architectural Foundation both serve as 

wonderful resources for cultural facts about the city as well 

as places that can connect you to various sightseeing tours. 

Both are just located blocks away from the hotel on 

Michigan Ave. 

When it comes to the stage, Chicago offers many options for 

cultural entertainment. The Tony award winning musical 

Billy Elliot will be continuing its run at the Ford Center 

for the Performing Arts and the Lion King returns for 

another run beginning October 22 nd at the Cadillac Palace 

Theater. If you haven’t already purchased tickets in 

advance, you may be able to find some deals to acquire 

tickets after you arrive. The Goodman Theater is always 

presenting quality plays throughout the year. Again, all of 

these establishments are within walking distance of the 

Conference site. Though it’s not within walking distance, 

the Second City comedy club is located just a few ‘L’ train 

stops away in the Pipers Alley Theater north of downtown. 

You will not want to miss this hilarious improv group which 

originated in Chicago and has jump started the careers of so 

many Saturday Night Live alumni. 

If you are a fan of educational pursuits, explore some of the 

nearby downtown museums such as the Art Institute (the 

new modern wing is wonderful) and the Museum Campus 

(the Adler Planetarium, Field Museum of Natural 

History, and the Shedd Aquarium). The Field Museum is 

the home of the famous Sue Dinosaur Exhibit that has 

traveled the country and returned to the Field earlier this 

year. 


Exhibitor Directory 

Addiction Professional 

Browse Table 

149 5th Avenue, 10th Floor 

New York, NY 10010 

Ph: 212-812-4674; Fax: 212-228-1308 

Addiction Professional is the essential 

resource supporting counselors, medical staff, 

supervisors, and other key decision-makers at 

addiction treatment and prevention organizations, 

providing timely guidance on care 

delivery, management strategies, and emerging 

trends affecting addiction services in the 

public and private sectors. 

If you are tight on budget—as some us of are—there are lots 

of opportunities for free exploration. For example, some 

noteworthy attractions are free to enjoy every day, including 

the Lincoln Park Zoo, the Oriental Institute, National 

Museum of Mexican Art, the Garfield Park Conservatory 

as well as the many ongoing events staged at the 

Cultural Center and along the lake front at the Navy Pier. 

Other attractions are free on specific days: The Chicago 

History Museum has free admittance on Mondays while 

the Museum of Contemporary Art is free on Tuesdays. 

The DuSable Museum of African American History is 

free every Sunday. During the week of the Conference, the 

Alder Planetarium will have free admission on Tuesday, 

October 26 and the Shedd Aquarium on both Monday, 

October 25 and Tuesday, October 26. Chicagoween—which 

involves various fun activities in the Loop area celebrating 

Halloween—will be ongoing during the entire month of 

October. 

Of course, one should not leave Chicago without sampling 

some of the food and music that the city is known for. 

Whether it’s the iconic Chicago style hot dog, Italian 

beef and pizza establishments or its more upscale steakhouses 

and ethnic restaurants, there will be plenty of 

options, some within blocks of the Hilton Chicago. Chicago 

has historically been influential in the jazz and blues scene. 

Please check out the Buddy Guys Legends Blues Club 

located just behind the hotel on Wabash Street for 

wonderful music. 

The Hospitality Committee will be present to warmly help 

you navigate the city as well as to tour some of the local 

OTPs (there will be a sign up sheet at the Hospitality table). 

Welcome to Chicago! 

Submitted by Tamika Whitehead, 2010 AATOD Conference 

Hospitality Committee Chair 

Addiction Treatment Providers 

Insurance Program 

Booth# 306 

555 North Lane, Suite 6060 

Conshohocken, PA 19428 

Ph: 610-941-9877; Fax: 610-941-9889 

RJWilletts@nsminc.com 

www.nsminc.com 

Addiction Treatment Providers Insurance 

Program (ATP) is an exclusive program for the 

Behavioral Health Treatment Industry. ATP 

offers a comprehensive suite of coverages to 

meet the unique needs of all addiction and 

mental health treatment facilities. Our 

program serves a wide range of inpatient, 

outpatient, and methadone maintenance facilities, 

including those facilities with larger and 

more diverse operations. 

AIT Laboratories 

Booth# 103 

2265 Executive Drive 

Indianapolis, IN 46241 

Ph: 317-243-3894; Fax: 317-243-2789 

info@aitlabs.com 

www.aitlabs.com 

AIT Laboratories offers state-of-the-art 

analyses for pain management, forensics, and 

pharmaceutical clients nationwide. AIT’s pain 

services include the DetectiMed® Panel, 

which is the most comprehensive urine panel 

available to monitor compliance, access to 

Ph.D.-level toxi cologists, cutting-edge technology, 

flexible billing options, and results via 

online reporting at www.AITLabs.com. 

Alkermes, Inc. 

Booth# 101 

852 Winter Street 

Waltham, MA 02451 

Ph: 781-609-6000; Fax: 781-609-5859 

Pamela.Osullivan@alkermes.com 

www.alkermes.com 

28

Alkermes, Inc. is a fully integrated biotechnol - 

ogy company that uses proprietary technologies 

and know-how to create innovative medicines 

designed to yield better therapeutic outcomes 

for patients with serious diseases, including 

central nervous system disorders, addiction 

and diabetes. For more information about 

Alkermes, please visit: www.alkermes.com. 

American Association for the Treatment 

of Opioid Dependence, Inc. (AATOD) 

Booth# 308 

225 Varick Street, 4th Floor 

New York, NY 10014 

Ph: 212-566-5555; Fax: 212-366-4647 

Edjohi@aol.com 

www.aatod.org 

The American Association for the Treatment of 

Opioid Dependence, Inc. (AATOD) was founded 

in 1984 to enhance the quality of patient care 

in treatment programs by promoting the 

growth and development of comprehensive 

opioid treatment services throughout the 

United States. AATOD works with federal agencies, 

state substance abuse authorities and 

agencies within the criminal justice system 

concerning opioid treatment policy in addition 

to coordinating activities with advocacy groups 

and treatment providers in all regions of the 

country. AATOD continues to work on behalf of 

all its members by expanding access to quality 

addiction treatment services. 

American Bio Medica Corporation 

Booth# 414 

122 Smith Road 

Kinderhook, NY 12106 

Ph: 518-758-8158/800-227-1243 

Fax: 518-758-8172 

info@abmc.com 

www.abmc.com 

ABMC is a manufacturer of accurate, simple, 

cost-effective point of collection tests that 

detect the presence or absence of abused 

drugs in urine or oral fluid, including a line of 

CLIA waived drug tests. Our products are 

manufactured in the US ensuring the highest 

quality. Visit our website at www.abmc.com. 

Ammon Analytical Laboratory, LLC 

Booth# 212 

1622 South Wood Avenue 

Linden, NJ 07036 

Ph: 908-862-4404; Fax: 908-862-0605 

nreyes@ammontox.com 

www.ammontox.com 

Ammon Analytical is a specialty toxicology 

laboratory. Our main focus is working with 

treatment centers that are dedicated in the 

treatment of opiate addiction. We are highly 

specialized in what we do so that we can offer 

services and pricing that you may not be 

getting from your existing laboratory. 

Atlantic Diagnostic Laboratories, LLC 

Booth# 324 

3520 Progress Drive, Suite C 

Bensalem, PA 19020 

Ph: 267-525-2470; Fax: 267-525-2488 

info@adllab.net 

www.adllab.net 

Atlantic Diagnostic Laboratories, LLC (ADL) 

was formed on May 1, 2008 as a result of the 

merger between four (4) clinical laboratories, 

each of which had been in business for at least 

30 years, and the acquisition of a forensic/toxicological 

laboratory. While ADL has become 

the largest privately owned 

clinical/forensic/toxicological laboratory in the 

greater Tri-State region surrounding the 

Philadelphia metropolitan area, they do in fact 

conduct business on a national basis with 

emphasis placed on the Pain Management and 

Drug and Alcohol Abuse (including Methadone 

and Buprenorphine Treatment Programs) 

arenas. 

Avee Laboratories 

Booth# 115 

14440 Myerlake Circle 

Clearwater, FL 33760 

Ph: 727-474-0600; Fax: 727-683-9412 

www.avee.com 

Bendiner & Schlesinger Inc. Medical 

Laboratories 

Booth# 204 

140 58th Street, Suite 8D 

Brooklyn, NY 11220 

Ph: 212-353-5111; Fax: 212-598-0907 

info@bendinerlab.com 

www.bendinerlab.com 

Bendiner & Schlesinger, Inc., a full-service 

laboratory, has more than 40 years experience 

in meeting the testing needs of treatment 

programs for opioid dependence throughout 

the U.S. Bendiner & Schlesinger, Inc. offers 

laboratory-based urine and oral-fluid drug 

screening, including complete differentiation 

and quantitation of positive screens of either 

specimen type. 

Brown Consulting, Ltd. 

Browse Table 

121 N. Erie Street 

Toledo, OH 43610 

Ph: 800-495-6786; Fax: 419-241-8689 

info@danbrownconsulting.com 

www.danbrownconsulting.com 

Since 1987, Brown Consulting, Ltd. has 

provided a range of Consulting Services for 

more than 400 organizations across 38 states. 

We specialize in Accreditation, Regulatory 

Compliance, Strategic Planning, Feasibility 

Analysis and more. Give us a call today at 800- 

495-6786. 

C&C Containers 

Booth# 203 

2607 Ledo Road 

Albany, GA 31707 

Ph: 229-869-6071; Fax: 229-903-0025 

info@cccontainers.net 

www.cccontainers.net 

We sell medication bottles and caps that you 

can afford without sacrificing the customer 

service that you deserve! 

Calloway Labs 

Booth# 404 

34 Commerce Way 

Woburn, MA 01801 

Ph: 781-224-9899; Fax: 781-569-0641 

sbuell@callowaylabs.com 

www.callowaylabs.com 

Calloway, one of the fastest growing clinical 

toxicology laboratories, specializes in proprietary 

testing protocols to address critical challenges 

facing medical professionals in pain 

management. Calloway is at the forefront of 

urine drug testing using the latest technology: 

Point-of-Care-Testing, high volume screening, 

in-house GC/MS, LC/MS/MS and LDTD/MS/MS 

confirmation and medical review. 

CAMH – Center for Addiction & 

Mental Health 

Browse Table 

33 Russell Street – Room 4088 

Toronto, Ontario M5S 2S1 Canada 

Ph: 416-535-8501 x6653; Fax: 416-593-4694 

CAMH’s catalogue caters to a community of 

readers that is broad and eclectic. Our readers 

are professionals: working in health, education, 

social work, law enforcement and the justice 

system and clients seeking to heal and empow - 

er themselves and clients’ friends and families. 

29

CARF International 

Booth# 304 

6951 East Southpoint Road 

Tucson, AZ 85756 

Ph: 520-325-1044; Fax: 520-318-1129 

bharrison@carf.org 

www.carf.org 

CARF International is an international, 

nonprofit accreditor of human service 

providers and networks. A provider earns 

accreditation by demonstrating conformance 

to CARF’s internationally recognized standards 

in areas that span the continuum of life. 

More than 6.5 million persons of all ages are 

served annually in CARF-accredited programs. 

Clinical Science Laboratory, Inc. 

Booth# 314 

51 Francis Avenue 

Mansfield, MA 02048 

Ph: 800-255-6106; Fax: 508-339-3540 

don@clinicalsciencelab.com 

www.clinicalsciencelab.com 

Clinical Science Laboratory is the premier 

toxicology laboratory for the testing needs of 

opioid addiction treatment facilities. We tailor 

drug screens, both urine and oral fluid, to meet 

your testing requirements, and do all clinical 

blood testing in-house. Our trademark is 

“Personalized Service with Professional 

Commitment Since 1974.” 

Computalogic, LLC 

Booth# 113 

20436 Route 19, Ste 620 Box 180 

Cranberry Twp, PA 16066 

Ph: 724-371-1199; Fax: 888-350-8858 

keith@computalogic.com 

www.computalogic.com 

MethodOne by Computalogic is the most 

comprehensive web based Addiction Software 

on the market. It is highly configurable, very 

flexible and extremely user-friendly software 

for the management of Opiate addiction treatment 

facilities and includes everything you 

need to manage your facility without the 

upfront costs that other software companies 

charge! 

Dominion Diagnostics 

Booth# 219 

211 Circuit Drive 

North Kingstown, RI 02852 

Ph: 877-734-9600 

www.dominiondiagnostics.com 

Dominion Diagnostics, a CAP-accredited and 

CLIA-certified national medical laboratory, is 

the premier laboratory provider of advanced 

clinical quantitative urine drug monitoring 

services for Addiction Treatment programs, 

Behavioral/Mental Health providers, Physician 

offices and Pain Management practices. 

Dominion is the exclusive provider of state-ofthe-art 

clinical reporting tools, including its 

new Comprehensive Analysis of Reported Drugs 

(CARD), that provide scientifically accurate 

reporting to assist clinicians in monitoring 

their patients’ adherence to a prescription drug 

regime and to also alert them to the presence 

of any drugs of abuse in the patient’s system. 

GlaxoSmithKline 

Booth# 201 

Three Franklin Plaza, 1600 Vine Street 

Philadelphia, PA 19101 

Ph: 800-366-8900 

www.gsk.com 

GlaxoSmithKline is a leading research-based 

pharmaceutical company with a powerful 

combination of skills to discover and deliver 

innovative medicines. We offer a number of 

programs to support effective health management 

strategies and improve patient care. 

Please visit our exhibit to learn more about our 

products. 

Harwoods Miami Safe Co 

Booth# 105 

7350 S.W. 45 Street 

Miami, FL 33155 

Ph: 305-389-0517; Fax: 305-266-5821 

jackbagwell@gate.net 

www.miamisafeandvault.com 

Nationwide sales and service. U.L. rated safes 

and vaults for the Pharmaceutical Industry. 

Illinois Department of Human Services 

Booth# 408 

Division of Alcoholism and Substance Abuse 

100 W. Randolph Street, Suite 5-600 

Chicago, IL 60601 

Ph: 312-814-6380; Fax: 312-814-2419 

Richard.weisskopf@illinois.gov 

http://www.dhs.state.il.us 

The Department of Human Services, Division 

of Alcoholism and Substance Abuse, is the 

state’s lead agency addressing the profound 

personal, social and economic consequences of 

alcohol and other drug abuse. DHS/DASA 

administers a network of 200 communitybased 

sites providing evaluation, diagnosis, 

treatment and rehabilitation to drug abusers 

and their families. 

Kols Containers Inc/OBerk New 

England 

Booth# 214 

1408 DeSoto Road 

Baltimore, MD 21230 

Ph: 800-457-5657; Fax: 410-646-5671 

jlineberry@kolscontainers.com 

www.oberk.com 

OBerk and Kols are Full Service Packaging 

Distributors. We supply “take-home” bottles 

and child resistant caps as well as tamperevident 

seals and dispensing cups. We have 

warehouses in West Haven, CT and Baltimore, 

MD with large inventories of bottles and caps 

to serve your packaging needs. 

Mallinckrodt (a Covidien company) 

Booth# 205 

675 James S. McDonnell Blvd. 

Hazelwood, MO 63042 

Ph: 314-654-3348; Fax: 314-654-7129 

cj.paulus@covidien.com 

www.covidien.com 

Mallinckrodt (a Covidien company) is one of 

the fastest growing pharmaceutical entities in 

the U.S. Our exclusive 5-step Vertical Integration 

Process means control of active ingredient 

production, formulation, manufacturing, packaging 

and distribution. We provide products to 

treat pain, ADHD, opiate and alcohol addiction, 

depression and insomnia. 

National Institute on Drug Abuse (NIDA) 

Booth# 313 

6001 Executive Blvd., Suite 5213 

Bethesda, MD 20892 

Ph: 301-594-6142; Fax: 301-443-7397 

jnolan1@nida.nih.gov 

www.drugabuse.gov 

The National Institute on Drug Abuse is a 

Federal agency charged with supporting 

research on the causes, prevention, and treatment 

of all aspects of drug abuse including 

AIDS. The results of the NIDA-funded research 

offer this country’s best hope for solving the 

30

medical, social, and public health problems of 

drug abuse and addiction. Publications and 

research opportunities supporting these 

efforts will be made available. 

Netalytics 

Booth# 310 

102 Trade Street 

Greer, SC 29651 

Ph: 864-416-0153; Fax: 864-416-0157 

messex@netalytics.com 

www.methasoft.com 

Methasoft® is an industry leading product for 

the management and provision of care in the 

opioid treatment arena. Methasoft® is a 

completely integrated system from patient 

check-in kiosk to billing. Methasoft® is fully 

automated, flexible software that utilizes 

leading technologies including Microsoft, NET 

Framework and SQL Server. 

Netsmart Technologies 

Booth# 200 

3500 Sunrise Highway, Suite D122 

Great River, NY 11739 

Ph: 800-472-5509; Fax: 614-799-3188 

info@ntst.com 

www.ntst.com 

Netsmart Technologies is the trusted partner 

for health and human services’ largest 

connected community of providers and 

payers. Netsmart Methadone software solutions 

provide a range of options for both standalone 

methadone clinics and organizations 

with an integrated methadone treatment 

program. More than 500 clinics nationwide use 

Netsmart’s solutions to enhance operational 

efficiencies, which ultimately lead to improved 

methadone treatment. 

NIATx 

Booth# 109 

Health Enhancement System Studies 

1513 University Avenue 

Madison, WI 53706 

Ph: 240-676-7224 

weaverm@cae.wisc.edu 

www.NIATx.net 

NIATx serves the addiction and mental health 

treatment field by making improvements to 

the cost and effectiveness of the care delivery 

system. NIATx has developed a process 

improvement model, designed specifically for 

behavioral health care, which enables 

providers to make simple changes that can 

substantially improve financial stability and 

outcomes. 

OraSure Technologies 

Booth# 322 

220 East 1st Street 

Bethlehem, PA 18015 

Ph: 484-892-0939 

jpirone@orasure.com 

www.orasure.com 

OraSure Technologies offers reliable and accurate 

oral fluid solutions for drug and alcohol 

testing. Companies choose the Intercept® Oral 

Fluid Drug Test for their testing programs for its 

fast and simple collection process. 

We also offer the QED Saliva Alcohol Test, an onsite, 

rapid, low cost alternative to breath or blood 

testing. 

Reckitt Benckiser Pharmaceuticals, 

Inc. 

Booth# 303 

10710 Midlothian Turnpike, Suite 430 

Richmond, VA 23235 

Ph: 732-919-1234; Fax: 732-919-2685 

Reckitt Benckiser Pharmaceuticals is at the 

forefront providing educational resources and 

treatment options to physicians and patients 

dealing with the chronic relapsing disease of 

opioid dependence. Please visit their exhibit 

where Reckitt Benckiser Managed Care 

Account Managers will be available to provide 

scientific information and answer your questions. 

Redwood Toxicology Laboratory, Inc. 

Booth# 305 

3650 Westwind Blvd. 

Santa Rosa, CA 95403 

Phone: 800-255-2159; Fax: 707-568-2860 

www.redwoodtoxicology.com 

Suzanne Bertolucci, Sales Director 

sbertolucci@redwoodtoxicology.com 

Redwood Toxicology Laboratory, Inc. (RTL) 

offers comprehensive, low cost drug and 

alcohol testing options. Our laboratory services 

include urine drug testing, oral fluid drug 

testing, steroid testing and more. RTL also 

sells Reditest® instant, on-site drug test products, 

the highest quality, most cost-effective 

devices in the industry. 

Rosecrance Health Network 

Booth# 307 

1021 N. Mulford Road 

Rockford, IL 61107 

Ph: 815-391-1000; Fax: 815-391-5041 

info@rosecrance.net 

www.rosecrance.org 

Rosecrance is a leading, nonprofit substance 

abuse treatment center dedicated to providing 

quality, evidence-based counseling in an environment 

that fosters lasting recovery. We offer 

a full continuum of prevention, intervention 

and treatment services. Some programs of note 

include gender-specific, trauma-based, cooccurring, 

and experiential therapies. Visit 

www.rosecrance.org for details. 

Roxane Laboratories, Inc. 

Booth# 315 

1900 Arlingate Lane 

Columbus, OH 43228 

Ph: 614-241-4141; Fax: 614-308-3587 

chris.ludgis@boehringer-ingelheim.com 

www.roxane.com 

Headquartered in Columbus, OH, Roxane laboratories 

is a recognized leader for the 

research, development, sales, and marketing of 

multisource pharmaceutical products. Specific 

to addiction treatment, Roxane offers 

Methadone HCI Oral Concentrate and 

Diskets® Dispersible Tablets as well as 

Buprenorphine HCI Sublingual Tablets. Please 

visit our exhibit to learn more about our products 

and services. 

SAMMS 

Booth# 416 

120 W. Madison, Suite 800 

Chicago, IL 60602 

Ph: 877-717-SAMM; Fax: 800-789-0954 

samms@priceconsultinginc.net 

www.sammssystem.com 

Substance Abuse and Medication Management 

System (SAMMS) is a customizable electronic 

medical record and complete clinic management 

system for Methadone, Buprenorphine and Drug 

Free Clinics. 

San Diego Reference Laboratory 

Booth# 320 

6122 Nancy Ridge Drive 

San Diego, CA 92121 

Ph: 858-550-7344; Fax: 858-677-7998 

www.SDRL.com 

31

San Diego Reference Laboratory is a clientfocused 

toxicology laboratory, specializing in 

drug of abuse testing. We offer specifically 

designed urine/saliva laboratory panels, serum 

methadone testing, and cost effective onsite 

products to accommodate your program’s 

needs. SDRL offers clients Quality Service, 

Accurate Test Results, Accessibility to Technical 

information, and Rapid Turn Around 

Time. 

SciLog, Inc. 

Booth# 309 

8845 South Greenview Drive, Suite 4 

Middleton, WI 53562 

Ph: 800-955-1993; Fax: 608-824-0509 

djohnson@scilog.com 

www.scilog.com 

The LabTec Methadone Dispensing Pump 

provides high precision, high accuracy, 

programmable medication dispensing capability 

by volume or weight. The LabTec 

dispensing pump comes with RH1 piston pump 

head which is powered by 3400 RPM motor, 

and is typically controlled via “client” based 

software on a PC. Existing software from 

several sources are currently used with the 

LabTec in methadone clinics worldwide. Our 

patented LabTec dispensing pump is used in 

methadone clinics, research labs, pharmaceutical 

labs, and food safety labs worldwide for 

accurate dispensing of liquids. 

SMART Management, Inc. 

Booth# 211 

66 Pavilion Avenue 

Providence, RI 02905 

Ph: 800-942-4540 ext 115; Fax: 401-780-2350 

mcarruthers@smartmgmt.com 

www.smartmgmt.com 

SMART’s Clinic Management Software System 

is a fully integrated package including Clinical, 

Medical & Financial functioning. SMART Software 

comes with the best Customer Support in 

the field – just ask our Customers! Before you 

make your next Software purchase, call 

SMART Management for a free on-site or web 

demonstration. 

Substance Abuse and Mental 

Health Services Administration 

Booth# 208 

11300 Rockville Pike 

Rockville, MD 20852 

Ph: 240-221-4058; Fax: 301-945-4296 

www.SAMHSA.gov 

32

Continuing Education 

SAMHSA is a public health agency within the 

Department of Health and Human Services. The 

agency is responsible for improving the accountability, 

capacity and effectiveness of the nation’s 

substance abuse prevention, addictions treatment, 

and mental health services delivery 

system. 

The Joint Commission 

Booth# 311 

One Renaissance Blvd. 

Oakbrook Terrace, IL 60181 

Ph: 630-792-5866; Fax: 630-792-4866 

echoi@jointcommission.org 

www.jointcommission.org/BHC 

Accreditation from The Joint Commission helps 

create a standards-based culture of excellence, 

assisting you in providing the safest, highest 

quality environment for those you serve. To learn 

more about how your organization can earn this 

respected “Gold Seal of Approval”, drop by 

booth #311, visit www.jointcommission.org/BHC 

or call (630) 792-5866. 

Tower Systems, Inc. 

Booth# 221 

17461 Irvine Blvd. Suite Y 

Tustin, CA 92780 

Ph: 714-731-0491; Fax: 714-731-8634 

jnielsen@towersys.com 

www.methadoneclinics.com 

If you’re tired of hearing unfulfilled promises or 

relying on software that has yet to be delivered, 

it’s time to open your eyes and take a good look at 

Tower Systems. With a host of CARF, JCAHO & 

COA accreditation tools, as well as HIPAA 

compliant 837 & 835 billing, it’s time to expect 

more from your methadone management software 

provider. 

VistaPharm 

Booth# 217 

2224 Cahaba Valley Drive, Suite B3 

Birmingham, AL 35242 

Ph: 205-981-1387; Fax: 205-980-4849 

info@vistapharm.com 

www.vistapharm.com 

VistaPharm manufactures and distributes quality 

methadone products. We offer oral concentrate, 

dispersible tablets, tablets, and powder 

methadone. Our personalized services set us 

apart in our industry. We are accessible to 

address your needs in an expedient manner. Stop 

by our booth to meet the VistaPharm staff. 

2010 Continuing Medical Education—16.5 

ASAM—This activity has been planned and implemented in accordance 

with the Essential Areas and Policies of the Accreditation Council for 

Continuing Medical Education (ACCME) through the joint sponsorship of 

the American Society of Addiction Medicine (ASAM) and the American 

Association for the Treatment of Opioid Dependence (AATOD). 

ASAM CME Committee 

Adam J. Gordon, MD, MPH, FACP, FASAM, Chair 

Edwin A. Salsitz, MD, Co-Chair 

Maris Andersons, MD 

R. Jeffrey Goldsmith, MD 

Jacob Bobrowski, MD, FAAFP Elizabeth F. Howell, MD 

Lawrence S. Brown, Jr., MD, FASAM Mark P. Schwartz, MD 

Anthony H. Dekker, DO, FASAM John C. Tanner, DO, FASAM 

James L. Ferguson, DO 

ASAM CME Committee Reviewers 

Edwin A. Salsitz, MD 

James L. Ferguson, DO 

The American Society of Addiction Medicine designates this educational 

activity for a maximum of 16.5 AMA PRA Category 1 Credit(s). Physicians 

should only claim credit commensurate with the extent of their 

participation in the activity. 

2010 Continuing Education Hours 

NAADAC—AATOD is an approved provider through NAADAC, the Association 

for Addiction Professionals, Provider #000218. This program 

meets the criteria for up to 33.25 hours of continuing education. 

NBCC—This program has been approved by the National Board for 

Certified Counselors for up to 33. 25 hours, Approval Number SP-1823. 

ASWB—AATOD, provider # 1044, is approved as a provider for social 

work continuing education by the Association of Social Work Boards 

(ASWB)—www.aswb.org, through the Approved Continuing Education 

(ACE) program. AATOD maintains responsibility for the program 

approved until 2013. Social workers will receive up to 33.25 continuing 

education clock hours. 

IAODAPCA—AATOD, program number 10202, is approved for Counselor 

I or II, Prevention I, Assessor I or II, MISA I, II or III, CCJP I or II, PCGC 

II, CAAP I or II, CRSS I or II, BRI II, MAATP I or II, RDDP units and is 

approved for a total of 32.25 Continuing Education Units. 

State of California, Department of Consumer Affairs—Approved Continuing 

Education Provider #4101. 

AATOD has submitted application to the following 

organization for continuing education approval: 

New York State Nurses Association (NYSNA), an accredited 

approver by the American Nurses Credentialing Center’s 

Commission on Accreditation.

Special Thanks 

The American Association for the 

Treatment of Opioid Dependence, Inc., 

and the 2010 Conference Planning 

Committee acknowledge and give 

special thanks to: 

Illinois State Division of 

Alcoholism and Substance 

Abuse (DASA) 

Illinois Association for 

Medication Assisted Addiction 

Treatment (IAMAAT) 

National Institutes of Health 

(NIH)—National Institute on 

Drug Abuse (NIDA) 

PLATINUM LEVEL SPONSOR 

GOLD LEVEL SPONSORS 

SILVER LEVEL SPONSORS 

Substance Abuse and Mental 

Health Services Administration 

(SAMHSA), Center for Substance 

Abuse Treatment (CSAT) 

Join us again! 

2012 

National Conference 

Paris Hotel 

Las Vegas, Nevada 

BRONZE LEVEL SPONSORS 

ADDITIONAL 

SPONSOR 

Professionally Managed by

Final Conference Program - aatod

Create successful ePaper yourself

Delete template?

Save as template?